The critical care management of spontaneous intracranial hemorrhage: a contemporary review by Airton Leonardo de Oliveira Manoel et al.
REVIEW Open Access
The critical care management of
spontaneous intracranial hemorrhage:
a contemporary review
Airton Leonardo de Oliveira Manoel1,2,3* , Alberto Goffi4,5, Fernando Godinho Zampieri6,7, David Turkel-Parrella1,
Abhijit Duggal8,9, Thomas R. Marotta1, R. Loch Macdonald10 and Simon Abrahamson2,11
Abstract
Spontaneous intracerebral hemorrhage (ICH), defined as nontraumatic bleeding into the brain parenchyma, is the
second most common subtype of stroke, with 5.3 million cases and over 3 million deaths reported worldwide in
2010. Case fatality is extremely high (reaching approximately 60 % at 1 year post event). Only 20 % of patients who
survive are independent within 6 months. Factors such as chronic hypertension, cerebral amyloid angiopathy, and
anticoagulation are commonly associated with ICH. Chronic arterial hypertension represents the major risk factor for
bleeding. The incidence of hypertension-related ICH is decreasing in some regions due to improvements in the
treatment of chronic hypertension. Anticoagulant-related ICH (vitamin K antagonists and the newer oral
anticoagulant drugs) represents an increasing cause of ICH, currently accounting for more than 15 % of all cases.
Although questions regarding the optimal medical and surgical management of ICH still remain, recent clinical trials
examining hemostatic therapy, blood pressure control, and hematoma evacuation have advanced our
understanding of ICH management. Timely and aggressive management in the acute phase may mitigate
secondary brain injury. The initial management should include: initial medical stabilization; rapid, accurate
neuroimaging to establish the diagnosis and elucidate an etiology; standardized neurologic assessment to
determine baseline severity; prevention of hematoma expansion (blood pressure management and reversal of
coagulopathy); consideration of early surgical intervention; and prevention of secondary brain injury. This review
aims to provide a clinical approach for the practicing clinician.
Background
Spontaneous intracerebral hemorrhage (ICH) is defined
as nontraumatic bleeding into the brain parenchyma
[1, 2], which can extend into the ventricles and into the
subarachnoid space [3]. ICH is the second most com-
mon subtype of stroke [3], accounting for 10–50 % of all
cases [4, 5], depending on the population, race, and re-
gion studied [6]. According to the “Global Burden of Dis-
eases, Injuries, and Risk Factors” report, there were 5.3
million cases and over 3.0 million deaths secondary to
ICH worldwide in 2010 [6, 7]. The case-fatality rate ranges
from 35 % at 7 days to 59 % at 1 year [8–10]. Half of fatal
cases occur in the first 48 hours after presentation [11,
12]. Survivors are often left with severe disability [9], with
less than 40 % of patients regaining functional independ-
ence [3]. The epidemiology of ICH may change in the fu-
ture with better control of risk factors such as
hypertension [13], but the use of newer anticoagulation
therapies may influence the acute management and pos-
sibly prognosis of the disease [14, 15].
ICH has been traditionally described as the subtype of
stroke with the poorest prognosis [10]. However, recent
observational reports suggested that self-fulfilling prog-
nostic pessimism may lead to withdrawal of life support
in patients who otherwise may have had an acceptable
clinical outcome if managed aggressively [11]. Part of the
pessimism surrounding the prognostication of hemorrhagic
stroke is hypothesized to be a tendency not to consider
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factors such as age, previous comorbidities, etiology of the
bleeding, and socioeconomic factors [12], which are known
to affect outcome [16].
Etiology and risk factors
The most important modifiable risk factor in spontaneous
ICH is chronic arterial hypertension [17]. Deep perforator
arteries in the pons, midbrain, thalamus, basal ganglia, and
deep cerebellar nuclei, chronically damaged by hyperten-
sion, are the most common locations for hypertensive
bleeding [18, 19]. Chronic hypertension is present in 50–
70 % of patients who develop ICH [20]. Patients with a sys-
tolic blood pressure (SBP) ≥160 mmHg or a diastolic blood
pressure ≥110 mmHg have a 5.5 (95 % CI 3.0–10.0) times
increased rate of ICH, compared with normotensive pa-
tients [21]. Besides hypertension, cerebrovascular amyloid
deposition (i.e., cerebral amyloid angiopathy) is associated
with ICH in older patients [22]. Intracranial hemorrhage
associated with cerebral amyloid angiopathy seldom occurs
in subjects younger than 60 years of age. The incidence sig-
nificantly increases thereafter, and is almost always associ-
ated with a lobar hemorrhage [23]. Coagulopathies (i.e., the
use of antithrombotic or thrombolytic agents, congenital
or acquired factor deficiencies) and systemic diseases, such
as thrombocytopenia, are possible causes of ICH. The use
of oral anticoagulants, especially vitamin K inhibitors
(i.e., warfarin), has increased coagulopathy-associated
ICH in recent years, accounting for more than 15 % of all
cases [14, 24].
Psychosocial, ethnic, and economic factors play a role
in the prevalence of cerebral hemorrhage, with ICH being
twice as common in low-income and middle-income coun-
tries compared with high-income countries [2, 19, 25].
Other identified risk factors for ICH include age (i.e., each
decade from 50 years of age is associated with a 2-fold
increase in the incidence of ICH) and an elevated alcohol
intake [20].
Etiologies of ICH to always consider include: intracra-
nial aneurysms (typically presenting as subarachnoid
hemorrhage); arteriovenous malformations (ICH is the
first presentation of AVMs in 60 % of cases); cerebral
venous sinus thrombosis and venous infarction; brain tu-
mors (<5 % of all ICH cases) including cerebral metastasis
(e.g., lung cancer, melanoma, renal cell carcinoma, thyroid
carcinoma, and choriocarcinoma) and primary CNS tu-
mors (e.g., glioblastoma multiforme and oligodendrogli-
omas); and drugs of abuse (e.g., cocaine, amphetamines).
Because of the differing etiologies of ICH, a rapid and
accurate diagnosis of the underlying etiology of ICH is
essential to direct appropriate management strategies.
Initial evaluation and clinical stabilization
According to the AHA/ASA guidelines [9] and the
Emergency Neurological Life Support protocols [26],
spontaneous intracranial hemorrhage is a medical emer-
gency and should be managed accordingly. The initial
management should focus on the following principles
(Fig. 1):
Fig. 1 Principles of ICH management. GCS Glasgow Coma Scale, SaO2 Oxygen arterial saturation, PaCO2 partial pressure of carbon dyoxide, ICP intracranial
pressure, CBC Complete Blood Count, PTT Partial Thromboplastin Time, INR international normalised ratio, VKAs Vitamin K inhibitors, NOACs newer oral
anticoagulants, LMWH lower molecular weight heparin, HTN hypertension, NCCT non contrast computed tomography, CTA computed tomography
angiography, MRI magnetic resonance imaging, MRA Magnetic Resonance Angiography, MRV Magnetic Resonance Venogram, DSA digital subtraction
angiography, ICH intracerebral hemorrhage, IVH intraventricular hemorrhage, NIHSS National Institutes of Health Stroke Scale, SBP systolic blood pressure,
EVD external ventricular drain
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1. ABC’s. Initial assessment and stabilization of airway
patency, breathing, and circulation.
2. Neuroimaging. Once clinical stability is achieved, an
urgent imaging study for rapid and accurate
diagnosis should be performed.
3. Standardized neurologic assessment to determine
baseline severity. The National Institutes of Health
Stroke Scale (NIHSS), if the patient is awake or
drowsy, or the Glasgow Coma Scale (GCS), if the
patient is obtunded or comatose, should be
performed and clearly documented.
4. Blood pressure management, reversal of
coagulopathy, and evaluation of the need for early
surgical intervention.
5. Frequent neurological examinations, at least every
hour [27, 28], to detect early clinical deterioration
and signs of increased intracranial pressure (ICP)
should be part of the routine initial management
algorithm.
Emergency radiologic diagnosis
The clinical presentation of ICH does not differ from acute
ischemic stroke, with the sudden onset of a focal neuro-
logical deficit. However, certain clinical findings signifi-
cantly increase the probability of intracranial hemorrhage,
such as coma, neck stiffness, seizures accompanying the
neurologic deficit, diastolic blood pressure > 110 mmHg,
vomiting, and headache. Cervical bruit and prior transient
ischemic attack decrease the probability of hemorrhagic
stroke. However, no single clinical finding or combination
of clinical findings can be considered absolutely diagnostic
[29]. Neuroimaging is therefore crucial in establishing the
diagnosis, and also for consideration of the underlying eti-
ology. Current guidelines recommend either noncontrast
computed tomography (CT) or magnetic resonance im-
aging (MRI) as the initial imaging test (Class I; Level of
Evidence A) [9]. CT is usually the first-line modality
given its wide availability and rapidity. Noncontrast CT
is highly sensitive and specific for acute blood [9]. Magnetic
resonance (gradient echo or T2 susceptibility-weighted
sequences) is as sensitive as noncontrast CT in detecting
acute blood, and is more sensitive in detecting previous
hemorrhage. The main drawbacks of MRI use in the acute
setting are cost and availability [30].
Computed tomography angiography (CTA) or
contrast-enhanced CT is also commonly employed in
the acute setting, combined with noncontrast CT, as a
strategy to detect active contrast extravasation into the
hematoma (spot sign—discussed later). Additionally, once
ICH is confirmed, additional imaging (e.g., CTA, magnetic
resonance angiography, or digital subtraction angiography
(DSA)) is recommended to search for the underlying eti-
ology (Additional file 1: Table S1), such as vascular malfor-
mations and brain tumors (Class IIa; Level of Evidence B)
[31, 32]. If cerebral venous sinus thrombosis is suspected
because of radiological findings such as unusual
hematoma location, relative increased edema volume,
or abnormal signal in the cerebral sinuses, CT venog-
raphy or magnetic resonance venography should be per-
formed [33].
In hypertensive patients older than 65 years with a well-
circumscribed hematoma located in the basal ganglia or
thalamus, the yield of such studies is low (2–3 %) and the
decision not to proceed with further diagnostics tests may
be reasonable [31, 32]. In young non-hypertensive pa-
tients, the following findings may warrant additional
work-up: presence of isolated intraventricular
hemorrhage (IVH) or subarachnoid hemorrhage, non-
circular hematoma shape, disproportionately excessive
edema, lobar location, identification of space-occupying
lesion, enlarged vessels or calcifications along the margins
of the ICH, and hyperattenuation within a dural venous
sinus or cortical vein along the presumed venous drainage
path. DSA remains the gold standard for identifying
underlying vascular lesions (e.g., cerebral aneurysms, ar-
teriovenous malformations), but CTA has shown an ac-
curacy of 89–100 % for determining secondary causes of
ICH [34, 35]. A recent study comparing CTA with DSA in
nonhypertensive patients younger than 45 years old dem-
onstrated excellent negative and positive predictive values
of CTA and CT venography (97.3 % and 100 %, respect-
ively) to establish or exclude vascular causes of ICH [36].
ICH volume, IVH, and hematoma location
The volume of blood on the initial noncontrast CT image
has a strong independent association with outcome. A
hematoma volume of 30 ml represents a cutoff point for
increased mortality [37, 38] and worse functional outcome
[37]. The ICH volume can be estimated using the ABC/2
formula [39], “where A is the greatest hemorrhage diam-
eter by CT, B is the diameter 90° to A, and C is the ap-
proximate number of CT slices with hemorrhage
multiplied by the slice thickness” [40]. Additionally, when
the hematoma volume is combined with the initial level of
consciousness assessed by the GCS, it can accurately pre-
dict 30-day mortality [37]. Patients with an ICH volume of
≥60 ml on the initial CT image and GCS ≤ 8 have a pre-
dicted 30-day mortality >90 %, compared with a mortality
of <20 % for patients with hematoma volume < 30 ml and
GCS ≥ 9 [37].
Both the presence and ongoing expansion of IVH are
powerful and independent predictors of functional out-
comes after ICH [41]. IVH is present in approximately
45 % of patients with spontaneous ICH. IVH is associated
with a lower probability of favorable outcome compared
with absence of IVH (15 % vs 31 %, p <0.00001) [42]. An
increase of more than 2 ml in IVH volume in the first
24 hours has been shown to be associated with an odds
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ratio (OR) for a poor outcome of 4.2 (95 % CI 1.06–16.63,
p = 0.0405) [43].
Hematoma location is another important factor that
affects outcome and treatment [26]. The most common
locations of hypertensive ICH are the basal ganglia
(caudate nucleus and putamen), thalamus, deep cerebellar
nuclei, midbrain, or pons (Fig. 2). Lobar hemorrhages are
often associated with structural changes such as cerebral
amyloid angiopathy, arteriovenous malformations, or brain
tumors.
Early neurological deterioration and hematoma
expansion
ICH patients are at risk for early neurological deterioration,
which is usually secondary to early hematoma expansion
or the development of acute hydrocephalus secondary to
IVH [44, 45]. The definition of early neurological deterior-
ation varies across studies, but it is usually described as
worsening from the initial neurological examination (e.g., a
change in the initial GCS or NIHSS scores) or progression
to death [46]. Early neurological deterioration occurs in up
to 40 % of patients within 48 hours, and is associated with
poorer long-term prognosis [46]. Mayer et al. [44] de-
scribed a prospective cohort of 46 noncomatose patients
(GCS ≥ 8) with ICH. Fifteen patients (33 %) developed
neurological deterioration, the majority (8/15, 53 %) during
the first day of hospitalization. Patients with neurological
deterioration had larger hematoma volume (mean volume:
45 ml vs 16 ml, p < 0.01) and mass effect on initial CT
(60 % vs 19 %, p < 0.01). The 30-day mortality was 47 %
in patients with neurological deterioration compared
with 3 % in those patients who did not acutely worsen
(p = 0.001). While the two most important predictors
on hospital admission of early neurological deterioration
are the hematoma volume and the presence of IVH, other
factors such as glucose concentration, fibrinogen levels,
and elevated SBP have been described [46].
Hematoma expansion is a major determinant of early
neurological deterioration, poor outcome, and death
[47–49]. Brott et al. [45] found that 26 % of ICH patients
developed substantial hemorrhage growth (defined as
≥33 % increase from baseline hematoma volume) be-
tween baseline and 1-hour CT scans (i.e., within 4 hours
of symptom onset). Additionally 12 % of the patients
developed hematoma growth between the 1-hour and
20-hour CT scans. Hemorrhage growth was significantly as-
sociated with early neurological deterioration. Hematoma
expansion is an independent determinant of poor outcome
Fig. 2 Deep intracranial hemorrhage. Common locations of hypertensive hemorrhage (clockwise: putamen, thalamus, cerebellum, and pons)
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and mortality [47], regardless of hematoma expansion def-
inition [48]. The early occurrence of hematoma growth
and subsequent neurological deterioration highlights
the importance of frequent neurological examinations
and early repeat CT scanning, which can alter medical
patient care or may trigger surgical interventions [28].
Prediction of hematoma expansion
Because hematoma expansion is a major determinant
of mortality and functional outcome, it could be poten-
tially beneficial to identify those patients at highest risk
of hematoma expansion. Prediction scores have been
published to predict hematoma expansion in ICH
(Additional file 1: Table S5) [50–52]. Prediction scores
share several common factors: shorter time from ICH on-
set to CT; warfarin use; and evidence of spot sign on CTA
(see later). The risk of hematoma expansion varies from
3.4–7.1 % in patients with no risk factors [50–52] to 70–
85.5 % in patients obtaining the maximum score [50–52].
(1)Time from ICH onset to CT. As discussed
previously, hematoma expansion tends to occur
early in the course of ICH [45], with the majority
(26 %) of significant hematoma growth happening
between baseline and 1-hour CT scans, compared
with only 12 % between 1-hour and 20-hour CT
scans. It is not surprising that a shorter time between
ICH onset and CT scan would appear to be a
predictor of hematoma expansion, because CT
scans performed more than 6 hours after ICH
onset would probably miss hematoma growth
that may have already occurred [53].
(2)Patients on warfarin (or with International
Normalized Ratio (INR) > 1.5) have an adjusted OR
of 4.04
(95 % CI 1.85–9.13) for hematoma expansion
compared with patients not on warfarin.
Warfarin-related ICH is discussed in the
anticoagulant-associated ICH (AAICH) section.
(3)“Spot sign” (Fig. 3). Initially described as contrast
extravasation on CTA [54–56], the term spot sign
has evolved to encompass foci of enhancement
within the hematoma on CTA [57]. Presently, the
term “contrast extravasation” should only be used
to describe the presence of contrast within the
hematoma on post-contrast CT [58, 59]. The identi-
fication of the spot sign (Fig. 3), and its sensitivity in
predicting hematoma expansion, is dependent on
several technical aspects of imaging acquisition, such
as the concentration of the contrast agent, the speed
of scanners, and, importantly, the timing between
the contrast injection and the image acquisition [60,
61]. The spot sign can be divided into the early spot
sign and the delayed spot sign. The early spot sign is
detected on the first-pass CTA, usually acquired in
the arterial phase within 30 seconds after contrast
injection. The delayed spot sign is detected on the
second-pass CTA, or post-contrast CT. The second-
pass CTA images (or venous phase of CTA), acquired
40 seconds to 3 minutes after contrast injection, in-
crease the yield of identifying a spot sign if not visual-
ized on the first-pass CTA [58, 59, 62–64]. In a
systematic review and meta-analysis [53] of 14 studies
of first-pass CTA, the spot sign had a sensitivity of
53 % (95 % CI 49–57 %), a specificity of 88 % (95 % CI
86–89 %), a positive likelihood ratio of 4.70 (95 % CI
3.28–6.74), and a negative likelihood ratio of 0.44
(95 % CI 0.34–0.58) for predicting hematoma expan-
sion. When a first-pass CTA was combined with a
post-contrast CT (data available for three studies)
better accuracy was achieved, with a sensitivity of
92 % (95 % CI 78–98 %), a specificity of 82 % (95 %
CI 74–88 %) a positive likelihood ratio of 4.89 (95 %
CI 3.29–7.27), a negative likelihood ratio of 0.10 (95 %
CI 0.04–0.31), a diagnostic OR of 52.62 (95 % CI
14.46–191.51), and a receiving operating curve
(ROC) of 0.94 (standard error 0.05) [57, 58, 65].
Interestingly, spot sign detected in the arterial
phase of CTA is associated with greater absolute
hematoma expansion [64]. These results support the
use of CT protocols that include non-contrast CT,
Fig. 3 Spot sign. Initially described as contrast extravasation on CTA,
the term has evolved to encompass foci of enhancement within the
hematoma on CTA (red arrow)
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followed by both CTA and post-contrast study [53].
Identification of a spot sign on CT may have several
clinical implications:
A. Identification of contrast extravasation and the
spot sign are potent and independent predictors
of hematoma expansion [60]. In the multicenter
prospective “Prediction of hematoma growth and
outcome in patients with ICH using the CT-
angiography spot sign” (PREDICT) study [66],
the presence of spot sign was associated with a
relative risk of 2.3 (95 % CI 1.6–3.1) for hematoma
expansion, defined as an absolute increase > 6 ml
or a relative increase > 33 % from baseline ICH
volume. However, identification of spot sign does
not necessarily infer definite hematoma expansion.
A spot sign score has been developed to help
predict hematoma expansion [62]. The score
includes: number of spot signs (1–2 or ≥3),
maximum axial dimension (1–4 mm or ≥5 mm),
and maximum attenuation in Hounsfield Units
(120–179 HU or ≥180 HU). A score of 0 indicates
that no spot sign was identified on CTA, and it has
been associated with minimum risk of hematoma
expansion (2 %). In patients with the maximum
score (4 points), the risk for hematoma expansion
approaches 100 % [62].
B. CTA spot sign is associated with both functional
outcome and mortality. In the PREDICT study
[66] patients with evidence of a spot sign on CTA
had a median 3-month modified Rankin Scale
(mRS) of 5 (severe disability—patient bedridden,
incontinent, and requiring constant nursing care
and attention), in contrast to a median mRS of 3
(moderate disability—patient requiring some help,
but able to walk without assistance) in spot-
sign-negative patients (p < 0.001). The 3-month
mortality was 43.4 % in the spot-sign-positive
group, compared with 19.6 % in the spot-sign-
negative patients (HR 2.4, 95 % CI 1.4–4.0,
p = 0.002). Likewise, in the spot sign score study
[63], the presence of spot sign was associated with
an increased risk of in-hospital mortality (55.6 %,
OR 4.0, 95 % CI 2.6–5.9, p < 0.0001) and with an
unfavorable functional outcome at 3 months
(50.8 %, OR 2.5, 95 % CI 1.4–4.3, p < 0.0014),
defined as mRS ≥ 4 (moderate severe disability—
patient unable to walk unassisted and unable to
attend to own bodily needs without assistance).
C. Patients with positive spot sign on CTA may
benefit from more aggressive treatment to reduce
hematoma expansion, which may decrease
mortality and improve functional outcome [60].
Studies are enrolling spot-sign-positive patients
for treatment with recombinant factor VIIa—Spot
Sign for Predicting and Treating ICH Growth
(STOP-IT) (ClinicalTrials.gov NCT00810888), and
Spot Sign Selection of Intracerebral Hemorrhage to
Guide Hemostatic Therapy (SPOTLIGHT)
(ClinicalTrials.gov NCT01359202)— and for
aggressive antihypertensive treatment (SCORE-
IT: NIH–NINDS R01NS073344) [67] (Additional
file 1: Table S4).
Clinical severity assessment
Routine use of ICH clinical grading scales to assess
baseline severity is useful in the standardization of initial
assessment and in communication between providers.
Scoring systems may allow for outcome risk stratification
based on patients’ presentation characteristics (Class I
recommendation) [9]. Several clinical grading scales
have been developed to risk-stratify and predict outcome
after spontaneous ICH [68]. The ICH score (Table 1) [38]
is the most widely used and externally validated ICH grad-
ing scale [68]. The ICH score was derived from a retro-
spective analysis of 152 spontaneous ICH patients who
presented to the University of California, San Francisco.
Five independent predictors of 30-day mortality were
identified and used to build the score: level of conscious-
ness according to the GCS; age; ICH volume; IVH; and
Table 1 Original ICH score and predicted 30-day mortality
according to total score
Component Points Total ICH score 30-day mortality (%)
Glasgow Coma Scale




≥80 1 1 7–13
<80 0
ICH volume (ml)
≥30 1 2 30–44
<30 0
Presence of intraventricular hemorrhage
Yes 1 3 56–78
No 0
Infra-tentorial origin of ICH
Yes 1 4 70–100
No 0
Total ICH score 0–6 5–6 100
The five independent predictors of 30-day mortality according to the original
ICH score are displayed in the first column (Glasgow Coma Scale, age, ICH
volume, intraventricular hemorrhage, and infra-tentorial location of ICH). The
total score is the sum of the five components, varying from 0 to 6 points
(column 3). The higher the total score (column 3), the higher the predicted
30-day mortality (column 4)
ICH intracerebral hemorrhage
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infra-tentorial location of ICH (Table 1) [38]. The GCS at
the time of transfer from the ED to the ICU (or to the op-
erating room) was found to be the strongest independent
predictor of 30-day mortality, and consequently given the
heaviest weight in the score [38]. The other four compo-
nents have similar strength of association to outcome, and
therefore the same weight in the grading scale. The choice
of an ICH volume of 30 ml was based on previously pub-
lished data [37]; larger volumes (≥60 ml) did not improve
the score’s performance, possibly due to significant con-
founding effects of other score components (e.g., GCS) on
larger hematomas [38]. The higher the score, the higher
the mortality, which ranges from 0–10 % in patients with
an ICH score of 0 to 100 % in patients with an ICH
score ≥ 5 [68]. However, the use of clinical grading scales
such as the ICH score should never be used in isolation to
limit interventions in the very acute initial management of
patients with ICH.
Patient disposition
Patients with ICH present management challenges from
both a general medical and a neurological perspective,
and they are at high risk of early deterioration [44, 45].
These patients may therefore benefit from initial moni-
toring and management in dedicated neuroscience
ICUs or dedicated stroke units (Class I recommendation)
[9, 69, 70]. In the INTERACT 2 study, fewer than 40 % of
both study groups were cared for in an ICU, with the ma-
jority of patients admitted to a stroke unit rather than an
ICU [71]. In a Swedish study including 105,043 patients
(all types of acute stroke) from 86 hospitals, care in a
stroke unit for patients with ICH was associated with
lower risk of death or institutional living after 3 months
(OR 0.60, 95 % CI 0.54–0.68) compared with other types
of wards [72]. ICH patients were among the subgroups
with the best relative effect (hazard ratio (HR) for death
0.61, 95 % CI 0.58–0.65). A systematic review and meta-
analysis of eight clinical trials comparing stroke unit care
with general ward care (2657 patients), showed that stroke
unit care reduced death or dependency (risk ratio (RR)
0.81, 95 % CI 0.471–0.92, p =0.0009, I2 = 60 %) [70].
Patients requiring advanced monitoring and complex care
such as external ventriculostomy drainage, ICP monitoring,
mechanical ventilation, or multimodal neuromonitoring
often require admission to the ICU.
Medical management of ICH
Several issues regarding medical and surgical manage-
ment of ICH remain unanswered. Recent clinical trials
examining hemostatic therapy, blood pressure control,
and hematoma evacuation have advanced our under-
standing of ICH management.
Blood pressure management
Chronic hypertension is the main risk factor for the
development of spontaneous ICH, which makes blood
pressure (BP) lowering physiologically intuitive as a
strategy to prevent hematoma expansion. However,
physiologic concern has been that excessive blood pres-
sure reduction could decrease cerebral perfusion pres-
sure (CPP) in the ischemic penumbra. Clinical studies,
however, have shown that this concern over the zone of
perihematoma ischemia is not well substantiated clinic-
ally [73, 74]. Kate et al. [75] randomized ICH patients to
two different SBP targets (aggressive group <150 mmHg,
and conservative group <180 mmHg). Patients under-
went CT perfusion study 2 hours after randomization,
and the raw imaging data were used to calculate cerebral
blood flow (CBF), maximum oxygen extraction fraction
(OEFmax), and the maximum cerebral metabolic rate of
oxygen (CMRO2). Despite significant difference in SBP
levels between the two groups (140.5 ± 18.7 mmHg vs
163.0 ± 10.6 mmHg, p < 0.001), perihematoma CBF,
OEFmax, and CMRO2 were not affected by aggressive BP
lowering [75]. Recently published clinical data have fur-
ther helped clarify the issue of BP thresholds in ICH. In
the INTERACT pilot study [76], spontaneous ICH pa-
tients within 6 hours of onset were randomly assigned
to early intensive BP-lowering strategy (target SBP =
140 mmHg) or “classic” BP management (target SBP =
180 mmHg). The study showed that acute aggressive
BP lowering was feasible and safe, with a marginal at-
tenuation in hematoma growth (1.7 ml). This pilot
study was followed by the INTERACT 2 trial (a phase
III trial), which enrolled 2794 patients with spontan-
eous ICH within 6 hours of hemorrhage [71]. Patients
were randomized to the SBP targets (aggressive treat-
ment <140 mmHg vs standard target <180 mmHg). No
differences in the primary composite outcome (mortality
or major disability) were found (52 % vs 55.6 %, p = 0.06).
Moreover, early intensive BP reduction was not associated
with decreased in hematoma growth, the main mechan-
ism by which aggressive BP treatment was believed to im-
prove outcome. However, a predefined ordinal analysis
showed lower mRS scores with intensive treatment (OR
for greater disability 0.87, 95 % CI 0.77–1.00, p = 0.04).
Two possible conclusions can be drawn from this study:
aggressive blood pressure lowering (SBP < 140 mmHg,
ideally within 1 hour from presentation) seems to be safe
in the acute phase of ICH (Class I; Level of Evidence A);
and a lower blood pressure target might have an impact
on long-term outcome, even if smaller than anticipated
(Class IIa; Level of Evidence B) [9]. The small effect on
hematoma growth and composite outcome observed in the
INTERACT 2 trial may be explained by small hematoma
volumes (11 ml), and, more importantly, by significant
delay in BP treatment initiation (median of 4 hours from
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ictus) and delayed achievement in blood pressure target in
the treatment group (6 hours of treatment). Therefore, it
may be extrapolated that approximately 10 hours passed
from hemorrhage onset to target BP achievement. By that
time, hematomas would probably have already expanded.
Additionally, only 34 % of patients in the treatment
group achieved the goal of SBP < 140 mmHg within
1 hour. The Antihypertensive Treatment of Acute Cerebral
Hemorrhage (ATACH) 2 trial has been published recently
[77], and compared two targets of SBP management in the
acute phase of ICH; SBP between 110 and 139 mmHg vs
140 and 179 mmHg. The trial was stopped early for futility
after the prespecified interim analysis, and included 1000
patients (sample size calculated: 1280 subjects). No differ-
ence in the rate of death and disability was found,
and the intervention group experienced higher rates
of renal adverse events within 7 days (9.0 % vs 4.0 %,
p = 0.002) [77]. Several differences between INTERACT 2
and ATACH 2 should be mentioned (Table 2). First,
the recruitment window was 6 hours in INTERACT
2 vs 3.5 hours (which was extended to 4.5 hours
throughout the study) in ATACH 2. The period of
blood pressure intervention was 7 days vs 24 hours in
the INTERACT 2 and ATACH 2 trials, respectively.
Table 2 INTERACT 2 [71] vs ATACH 2 [77] studies
INTERACT 2 (n = 2794) ATACH 2 (n = 1000)
Control Intervention Control Intervention
Number of enrolled patients 1430 1399 500 500
Treatment target (SBP in mmHg) <180 <140 140–179 110–139
Inclusion criteria GCS > 5 ICH (volume < 60 cm3), GCS score≥ 5
Primary outcome Death or major disability (mRS = 3–6) at
3 months
Death or disability (mRS = 4–6) at 3 months
Recruitment window 6 hours 4.5 hours
Medications used to lower blood pressure Urapidil: 32.5 % Nicardipine ± labetalol







Period of blood pressure intervention 7 days 24 hours
Time goal of blood pressure lowering 1 hour 2 hours
Mean interval between symptom onset and randomization 3.7 hours 3.7 hours 3.0 hours 3.0 hours
Systolic blood pressure at presentation (mmHg) 179 ± 17 179 ± 17 201.1 ± 26.9 200 ± 27.1
Mean systolic blood pressure achieved (mmHg) 164 within 1 hour 150 within 1 hour 141.1 ± 14.8 (2 hours) 128.9 ± 16 (2 hours)
153 within 6 hours 139 within 6 hours
Primary treatment failurea (%) 66 12.2
Baseline hematoma volume (ml) 11 11 10.2 10.3
Asian (%) 68.0 67.7 57.0 55.4
Death or disability (%)—mRS = 3–6 55.6 52.0 56.1 56.2
Modified Rankin Scale (%)
0 7.6 8.1 7.1 5.0
1 18.0 21.1 19.6 19.8
2 18.8 18.7 17.3 19.1
3 16.6 15.9 18.3 17.5
4 19.0 18.1 26.5 26.0
5 8.0 6.0 4.2 5.8
6 12.0 12.0 7.1 6.9
aPrimary treatment failure was defined as target SBP < 140 mmHg not achieved within 1 hour of randomization in the intensive-treatment group in the INTERACT
2 trial or within 2 hours in the ATACH 2 trial
GCS Glasgow Coma Scale, ICH intracerebral hemorrhage, mRS modified Rankin Scale, SBP systolic blood pressure
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Also, the studies started from different levels of SBP
on randomization: 179 mmHg vs 200 mmHg respect-
ively. Importantly, the mean minimum SBP achieved
within 2 hours in the control group of ATACH 2 was
similar to the mean SBP achieved within 6 hours in
the intervention group of INTERACT 2 (141 mmHg
vs 139 mmHg, respectively). In summary: the control
group in the ATACH 2 trial achieved similar blood
pressure levels compared with the intervention group
of INTERACT 2 (141 mmHg vs 139 mmHg); the
ATACH 2 trial therefore compared 140 mmHg vs
129 mmHg; and the patients included in both studies
had small hematomas (approximately 10 ml), making
those hematomas less likely to expand [44]. Rapid inten-
sive blood pressure lowering might still be beneficial to
patients with higher risk of hematoma expansion (e.g., lar-
ger hematomas, positive spot sign) [44, 60]. In conclusion,
acute lowering of SBP to 140 mmHg is safe [9], but it does
not seem to improve functional outcome, and SBP levels
of 130 mmHg might be associated with increased compli-
cations. Additionally, some observational studies have
demonstrated the common occurrence of small ischemic
lesions on diffusion-weighted MRI after ICH. The impact
of these ischemic lesions on functional outcome and their
relationship with acute blood pressure lowering vary
across those studies, and causality is not well established
[78]. Currently, no specific anti-hypertensive agent is con-
sidered universally superior. Several agents were used in
the INTERACT 2 trial [71], such as an alpha-adrenergic
antagonist (urapidil, 32.5 %), calcium channel blockers
(nicardipine or nimodipine, 16.2 %), combined alpha- and
beta-blocker (labetalol, 14.4 %), venodilators (nitrogly-
cerin, 14.9 %), a diuretic (furosemide, 12.4 %), and arterial
vasodilators (nitroprusside, 12.1 %; hydralazine 5.9 %).
The ATACH 2 trial administered nicardipine by intraven-
ous infusion, starting at a dose of 5 mg/hour, which was
increased by 2.5 mg every 15 minutes (maximum dose of
15 mg/hour), until the target SBP was achieved. Intraven-
ous labetalol was added as second-line agent, if the SBP
target was not reached, despite the maximum dose of
nicardipine [77]. Nicardipine and labetalol are the most
common drugs used in North America; both agents ap-
pear to be safe [79], but nicardipine might be more
effective in reaching and maintaining the target BP [80].
However, local drug availability and drug approval is a
practical consideration.
Anticoagulant-associated ICH
The use of anticoagulants has significantly increased in
the last decades, leading to a 3-fold increase in the inci-
dence of anticoagulant-related intracranial hemorrhage
[14]. Patients experiencing ICH on antithrombotic
agents have an increased risk for hematoma expansion
and higher risk of death and poor outcome [24, 81]. In
AAICH, the main goals are: withholding the culprit
drug; reversing the drug effect by the administration of
antidote when available; and monitoring the effective-
ness of anticoagulation reversal with laboratory tests.
However, the laboratory correction of coagulopathy may
not be associated with the reversal of coagulopathy in
vivo [40].
a. Warfarin is responsible for 9–14 % of all cases of
ICH [82], with an annual risk of warfarin-related
ICH of between 0.3 and 3.7 % when the INR is
between 2 and 4.5 [83] (Table 3). Patients on
long-term warfarin have up to an 11-fold higher
risk of ICH compared with patients not taking
anticoagulants [84]. Increased age (≥70 years) [84, 85],
a history of chronic hypertension [85], and the
concomitant use of antiplatelet therapy (APT)
[86] are risk factors for warfarin-related ICH.
Bleeding risk scores (e.g., HAS-BLED) may help
assess the risk of major bleeding in patients with
atrial fibrillation [87]. Warfarin-related ICH is also
associated with larger hematoma size [88] and
higher mortality rates compared with patients
without coagulopathy [81, 89]. For patients with
warfarin-related ICH and elevated INR (>1.4),
urgent coagulopathy reversal is warranted. Vitamin K,
given as a slow intravenous infusion (5–10 mg over
30 minutes), can completely reverse the warfarin
effect. However, it can take up to 24 hours to
completely reverse warfarin effect, and so its use as
sole therapy is associated with increased risk of
hematoma expansion, and is not recommended [9].
Currently, there are two other treatment options to
acutely reverse the warfarin effect: the transfusion of
fresh frozen plasma (FFP) or the use of prothrombin
complex concentrate (PCC). FFP contains all
coagulation factors but several transfusion-related
complications, such as allergic reactions, possibility of
infectious disease transmission, transfusion-related
acute lung injury and transfusion-related
circulatory overload could occur. More importantly,
the time consumed to thaw, cross-match, and
transfuse the appropriate dose (10–40 ml/kg) makes
the use of FFP for the acute reversal of warfarin-re-
lated ICH less appealing and less effective than
the use of PCC [90]. PCC is a virally inactivated
preparation of concentrated coagulation factors
pooled from healthy donors. Some PCC preparations
contain factors II, IX and X (three-factor PCC),
while some other preparations also contain higher
concentrations of factor VII (four-factor PCC).
Coagulation factors can be presented in the inactivated
or activated forms, depending on the formulation
(Additional file 1). Dosing is usually based on factor IX
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Table 3 Anticoagulants and reversal strategies
Drug Target Elimination and
half-life (hours)
Rate of ICH Monitoring
coagulation tests








0.3–1.1 % [90] Good linear
correlation PT/INR
Vitamin K Not dialyzable Withhold VKA + intravenous vitamin K +
replace vitamin K–dependent factors (three-
or four-factor PCC IV or FFP if PCCs are not
available), and correct the INR (keep INR <
1.4) (Class I; Level of Evidence C) [9]
92 % renal
elimination
Vitamin K 10 mg IV
associated with 4-FPCC
20 IU/kg (or FFP = 10–
15 ml/kg, if PCC is not
available)
PCCs might be considered over FFP
(Class IIb; Level of Evidence B) [9]
20–60 Goal: INR < 1.4 [90] rFVIIa is not recommended for VKA reversal
in ICH (Class III; Level of Evidence C) [9]
Unfractionated heparin, LMWHs, and heparinoids
UFH Binds and activates
antithrombin (which
blocks coagulation








Protamine sulfate 1 mg of
protamine per 100 units of
UFH infused over the
preceding 3 hours
Not dialyzable Protamine sulfate—1 mg for every 100 units
of heparin given in the previous 2–3 hours
with a maximum single dose of 50 mg




If aPTT is still elevated, repeat administration
of protamine at a dose of 0.5 mg protamine
per 100 units of UFH (Conditional
recommendation, low quality of evidence)
[90]
Reversal of prophylactic SC heparin only if






factors Xa and IIa)





Anti-factor Xa Protamine sulfate partially
reverses (60 %) LMWH
effect. One mg protamine
for every 1 mg enoxaparin
Not dialyzable Strong recommendation, moderate quality
evidence [90]
4.5 hours Protamine sulfate 1 mg per 1 mg of
enoxaparin (maximum single dose of
50 mg—if enoxaparin was given within
8 hours)
Protamine sulfate 0.5 mg of protamine per
1 mg of enoxaparin (if enoxaparin was
given within 8–12 hours)





factors Xa and IIa)
Renal Not established Anti-factor Xa Protamine sulfate partially
reverses (60 %) LMWH
effect. One mg protamine
for every 100 anti-Xa IU
dalteparin
Not dialyzable Protamine sulfate 1 mg per 100 IU of
dalteparin administered in the past 3–5






















factors Xa and IIa)
Renal Not established Anti-factor Xa Protamine sulfate partially
reverses (60 %) LMWH
effect. One mg protamine
for every 100 anti-Xa IU
nadroparin
Not dialyzable Protamine sulfate 1 mg per 100 IU of
nadroparin administered in the past 3–5
half-lives (maximum 50 mg) (Strong recom-












50–77 % renal Not established Anti-factor Xa None Activated PCC
(FEIBA 20 units/
kg)
aPCC 20 IU/kg (Conditional











Protamine sulfate is not recommended
(Strong recommendation, low-quality
evidence) [90]



























aPCC (50 units/kg) or four-factor PCC
(50 units/kg) (Conditional recommendation,
low-quality evidence) [90]
rFVIIa or FFP are not recommended in direct
thrombin inhibitor-related ICH (Strong





















aPCC (50 units/kg) or four-factor PCC








rFVIIa or FFP are not recommended in direct




















Idarucizumab 5 g IV in two divided doses if
dabigatran was administered within 3–5


















is affected in a
nonlinear way
dabigatran), in two doses
of 2.5 g IV 15 minutes
apart
recommendation, moderate quality of
evidence) or in the presence of RF leading
to continued drug exposure beyond the
normal 3–5 half-lives (Strong recommenda-
tion, moderate quality of evidence)
















Hemodialysis if idarucizumab is not available
(Conditional recommendation, low-quality
data)





45 % SDH, and















2 hours (12 hours
with renal
impairment)
Not established aPTT None Dialyzable aPCC (50 units/kg) or four-factor PCC
(50 units/kg) (Conditional recommendation,
low-quality evidence) [90]
rFVIIa or FFP are not recommended in direct
thrombin inhibitor-related ICH (Strong
recommendation, low-quality evidence) [90]




















Currently, there is no FDA-
approved specific antidote































Activated charcoal (50 g) within 2 hours of
ingestion (Conditional recommendation,
very low-quality evidence) [90]
aPCC (50 units/kg) or Four-factor PCC
(50 U/kg) or activated PCC (50 U/kg) if ICH
happened within 3–5 half-lives of drug or if
liver failure (Conditional recommendation,
low-quality evidence) [90]


























Table 3 Anticoagulants and reversal strategies (Continued)
prothrombin to
thrombin
7 to 11 hours - < 0.5 % /year Rivaroxaban levels
linearly increase
PT and aPTT levels




























Activated charcoal (50 g) within 2 hours of
ingestion (Conditional recommendation,
very low-quality evidence) [90]
Four-factor PCC (50 U/kg) or activated PCC
(50 U/kg) if ICH happened within 3–5 half-
lives of drug or if liver failure (Conditional
recommendation, low-quality evidence) [90]
Four-factor PCC or activated PCC over rFVIIa
(Conditional recommendation, low-quality
evidence) [90]

















Currently, there is no FDA-
approved specific antidote






























Activated charcoal (50 g) within 2 hours of
ingestion (Conditional recommendation,
very low-quality evidence) [90]
Four-factor PCC (50 U/kg) or activated PCC
(50 U/kg) if ICH happened within 3–5 half-
lives of drug or if liver failure (Conditional
recommendation, low-quality evidence) [90]




Aspirin Irreversible COX-1 and














The usefulness of platelet
transfusions in ICH patients






DDAVP 0.4 μg/kg IV (Conditional
recommendation, low-quality evidence) [90]
Platelet transfusion is not recommended
(Conditional recommendation, low-quality
evidence) [90]
Platelet transfusion for patients who will
undergo a neurosurgical procedure
(Conditional recommendation, moderate
quality of evidence) [90]
DDAVP can be used in addition to platelet












Table 3 Anticoagulants and reversal strategies (Continued)
neurosurgical procedure (Conditional
recommendation, low-quality evidence) [90]















The usefulness of platelet
transfusions in ICH patients






DDAVP 0.4 μg/kg IV (Conditional
recommendation, low-quality evidence) [90]
Platelet transfusion is not recommended
(Conditional recommendation, low-quality
evidence) [90]
Platelet transfusion for patients who will
undergo a neurosurgical procedure
(Conditional recommendation, moderate
quality of evidence) [90]
DDAVP can be used in addition to platelet
transfusion in patients who will undergo
neurosurgical procedure (Conditional
recommendation, low-quality evidence) [90]















The usefulness of platelet
transfusions in ICH patients






DDAVP 0.4 μg/kg IV (Conditional
recommendation, low-quality evidence) [90]
Platelet transfusion is not recommended
(Conditional recommendation, low-quality
evidence) [90]
Platelet transfusion for patients who will
undergo a neurosurgical procedure
(Conditional recommendation, moderate
quality of evidence) [90]
DDAVP can be used in addition to platelet
transfusion in patients who will undergo
neurosurgical procedure (Conditional
recommendation, low-quality evidence) [90]






to 4–5 days after
repeated doses)










The usefulness of platelet
transfusions in ICH patients






DDAVP 0.4 μg/kg IV (Conditional
recommendation, low-quality evidence) [90]
Platelet transfusion is not recommended
(Conditional recommendation, low-quality
evidence) [90]
Platelet transfusion for patients who will
undergo a neurosurgical. procedure
(Conditional recommendation, moderate
quality of evidence) [90]
DDAVP can be used in addition to platelet
transfusion in patients who will undergo
neurosurgical procedure (Conditional















The usefulness of platelet
transfusions in ICH patients






DDAVP 0.4 mcg/kg IV (Conditional
recommendation, low-quality evidence) [90]
Platelet transfusion is not recommended
(Conditional recommendation, low-quality
evidence) [90]
Platelet transfusion for patients who will












Table 3 Anticoagulants and reversal strategies (Continued)
(Conditional recommendation, moderate
quality of evidence) [90]
DDAVP can be used in addition to platelet
transfusion in patients who will undergo
neurosurgical procedure (Conditional
recommendation, low-quality evidence) [90]

















The usefulness of platelet
transfusions in ICH patients






DDAVP 0.4 mcg/kg IV (Conditional
recommendation, low-quality evidence) [90]
Platelet transfusion is not recommended
(Conditional recommendation, low-quality
evidence) [90]
Platelet transfusion for patients who will
undergo a neurosurgical procedure
(Conditional recommendation, moderate
quality of evidence) [90]
DDAVP can be used in addition to platelet
transfusion in patients who will undergo
neurosurgical procedure (Conditional





















The usefulness of platelet
transfusions in ICH patients










with a history of
antiplatelet use
is uncertain
DDAVP 0.4 μg/kg IV (Conditional
recommendation, low-quality evidence) [90]
Platelet transfusion is not recommended
(Conditional recommendation, low-quality
evidence) [90]
Platelet transfusion for patients who will
undergo a neurosurgical procedure
(Conditional recommendation, moderate
quality of evidence) [90]
DDAVP can be used in addition to platelet
transfusion in patients who will undergo
neurosurgical procedure (Conditional
recommendation, low-quality evidence) [90]
aPTT activated partial thromboplastin time, ECT ecarin clotting time, ICH intracerebral hemorrhage, INR International Normalized Ratio, PCC prothrombin complex concentrate, PT prothrombin time, TT thrombin time,
LMWH low-molecular-weight heparin, UFH unfractionated heparin, RF renal failure, GFR glomerular filtration rate, BID two times a day, SDH subdural hematoma, SAH subarachnoid hemorrhage, HR heartrate, ACT acti-












administered and it is usually adjusted by weight and/
or INR, although fixed doses of at least 20 UI/kg
of factor IX have been reported to be effective
[91]. Four-factor PCC might be more effective in
reversing warfarin effect than three-factor PCC
[92, 93]. A list of some four-factor PCC products
available in Canada, the USA, and Europe is presented
in Additional file 1. PCCs are effective for rapid
reversal of anticoagulation due to warfarin use
and are considered the first-choice option in some
guidelines [94, 95]. Hickey et al. [96] showed in a
retrospective cohort study that the median time
for INR reversal was significantly shorter with
four-factor PCC when compared with FFP
(5.7 hours vs 11.8 hours, respectively, p < 0.0001).
Additionally, FFP was associated with higher incidence
of serious adverse events, especially heart failure
(19.5 % vs 9.7 %, p = 0.014; relative risk 2.0, 95 % CI
1.1–3.5). In a phase IIIb study, Sarode et al. randomized
202 patients with active warfarin-related major bleeding
to four-factor PCC or FFP. Rapid INR reduction,
defined as the INR correction (≤1.3) at 0.5 hours
after the end of infusion, occurred in 62.2 % of
cases with four-factor PCC and only in 9.6 % of
patients who received FFP transfusion [97].
Although the use of recombinant activated factor
VII (rFVIIa) has been described as a possible option
for warfarin-related coagulopathy reversal, rFVIIa
does not replace the levels of other vitamin K-
dependent factors and has a short half-life. Current
guidelines therefore do not recommend its use for
reversal of warfarin-related ICH. Additionally, it is
15 times more expensive than FFP and at least 3.5
times more expensive than PCC, and is associated
with a higher risk of INR rebound [98]. In summary,
patients with warfarin-related ICH and elevated INR
should have vitamin K antagonist withheld, and
should receive vitamin K (10 mg IV over 30 minutes)
concomitantly with PCC guided by INR level or
weighted-base dosing (20 UI/kg). If PCC is not
available, FFP should be administered in a dose of
10-40 ml/kg. rFVIIa is not recommended in this
clinical scenario.
b. Unfractionated heparin (UFH) and low molecular
weight heparins (LMWHs). UFH prevents fibrin
formation by indirectly inhibiting factors Xa and IIa
(thrombin) through the activation of antithrombin.
Heparin-related ICH occurs in approximately
0.1–0.2 % of patients on continuous infusion of
UFH for a non-neurological indication. For patients
who develop ICH while on UFH infusion, heparin
reversal is warranted. Heparin infusion should be
immediately interrupted and protamine sulfate should
be administered at a dose of 1 mg for every 100 units
of heparin given in the previous 2–3 hours (maximum
single dose of 50 mg). A repeat dose of 0.5 mg of
protamine per 100 units of UFH may be given if the
aPTT remains elevated [90]. Similarly to UFH,
LMWHs also bind and activate antithrombin but have
less effect on thrombin compared with UFH, although
approximately the same effect on factor Xa. Protamine
appears to only partially neutralize the anti-factor Xa
activity of LMWH and therefore, in case of need for
reversal, this cannot be done completely. The main
goal of LMWH reversal is discontinuation of the drug,
although protamine use can be attempted. For
enoxaparin given within 8 hours, protamine sulfate
should be administered at the dose of 1 mg per 1 mg
of enoxaparin (maximum single dose of 50 mg); for
enoxaparin given within 8 and 12 hours, a dose of
0.5 mg of protamine per 1 mg of enoxaparin should
be administered. Beyond 12 hours of enoxaparin
administration, protamine administration is not
suggested. For dalteparin or nadroparin, protam-
ine sulfate should be given at a dose of 1 mg per
100 IU of dalteparin/nadroparin administered in the
past 3–5 half-lives (maximum single dose of
50 mg). Factor VIIa (90 μg/kg) can be used if pro-
tamine is contraindicated or in LMWH-related
ICHs that are refractory to protamine [90].
c. Antiplatelet agents. The literature on APT and its
association with outcomes after ICH is still
controversial. Several reports described the
association of antiplatelet agent use with hematoma
expansion and worse clinical outcome, including
increased mortality rate [99–101]. However, more
recent studies reported that patients on antiplatelet
agents prior to ICH have similar rates of hematoma
expansion compared with patients not receiving
these agents, and the functional outcome may be
independent of antiplatelet use [102–104]. For
example, in the Cerebral Hematoma and NXY-059
Treatment (CHANT) trial, a secondary analysis of
the placebo arm found no association between APT
use and ICH outcomes [102]. Because it remains
controversial whether APT influences hematoma
expansion or functional outcome, the clinical utility
of its reversal is uncertain [105]. In patients with
ICH and on APT, the agent should be discontinued
immediately. Some observational studies suggested
potential benefit from platelet transfusion [106].
Recently, Baharoglu et al. [107] published the results
of the PATCH study, the first randomized, open-label,
phase 3 trial investigating the effect of platelet
transfusion in patients with spontaneous ICH,
who were receiving APT. The study included 190
participants from the Netherlands, the UK, and
France. The study showed increased odds of a
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shift towards death or dependence at 3 months in
the group of patients receiving platelet transfusion
compared with the standard care group (adjusted
common OR 2.5, 95 % CI 1.18–3.56, p = 0.0114).
Secondly, more serious adverse events were reported
in patients who received platelet transfusion (42 %),
compared with 29 % in patients who received
standard care alone. Interestingly, the two groups
showed a difference in hematoma volume, although
this was not significant (13.1 (5.4–42.4) ml in the
intervention group vs 8.0 (4.4–25.8) ml in the
standard of care group). In the post-hoc analysis
the primary outcome remained unchanged when
adjusted for ICH volume at baseline, but there
was an apparent potential benefit for platelet
transfusion as the hematoma volume increased;
however, the very small size of the population
precluded a better-powered exploratory analysis.
Until the results of another similar randomized
trial (ClinicalTrials.gov NCT00699621) are available,
platelet transfusion should be considered not beneficial
but rather potentially harmful for people taking APT
and such decisions should be considered on an
individual basis [9]. For example, many authors
recommend platelet transfusion only for patients
with aspirin-associated or ADP inhibitor associated
ICH and for whom an emergency neurosurgical
procedure is planned [108].
A recent pilot study evaluated the role of
desmopressin (DDAVP) to improve platelet function
in patients with ICH and reduced platelet activity or
on aspirin therapy [109]. Desmopressin (0.4 μg/kg IV
given over 30 minutes) increased platelet activity, as
measured by von Willebrand factor antigen and
closure times (PFA-100 with epinephrine), 1 hour
after DDAVP administration. The DDAVP effect
may be short lived, however, and platelet function
abnormalities may return within 3 hours [110].
Based on these limited data, a single dose of
DDAVP (0.4 μg/kg IV given over 30 minutes) may be
considered for patients with aspirin-associated, COX-
1 inhibitor-associated, or ADP receptor inhibitor-
associated ICH.
d. New oral anticoagulants
– Factor Xa inhibitors. These oral anticoagulant
agents (e.g., rivaroxaban, apixaban, and edoxaban)
act as direct factor Xa inhibitors and prevent
factor Xa-dependent conversion of prothrombin
to thrombin. Current indications include primary
stroke prevention (i.e., in nonvalvular atrial
fibrillation), treatment of deep vein thrombosis
and pulmonary embolism, and secondary
prevention of venous thromboembolism (VTE)
[108, 111]. Compared with warfarin, factor Xa
inhibitors have shown a lower risk of ICH
(Table 3). However, currently there is no specific
antidote commercially available for this class of
drug, and most information on their reversal is
limited to ex-vivo and in-vivo studies on healthy
volunteers and animal models of bleeding.
Current recommendations suggest immediate
discontinuation of the drug followed by the
administration of four-factor PCC (50 U/kg) or
activated PCC (50 U/kg) in the case of patients
presenting within 3–5 terminal half-lives of the
drug or in the presence of liver failure. In case
of recent ingestion (within 2 hours), 50 g of
activated charcoal is recommended [108].
– Direct thrombin inhibitor reversal. Available
direct thrombin inhibitors include competitive
direct thrombin inhibitor (e.g., oral dabigatran),
reversible direct thrombin inhibitors (argatroban
and bivalirudin, both intravenous only), and
irreversible direct thrombin inhibitors (e.g.,
desirudin SC and lepirudin IV). Their main current
indications include primary stroke prevention
in patients with non-valvular AF, treatment of
VTE, and management of heparin-induced
thrombocytopenia [108]. Data on the incidence
and outcomes of direct thrombin inhibitor-related
ICH is scant. Dabigatran seems to be associated
with an ICH rate of 0.2–0.3 %/year, which is
lower compared with warfarin [108]. Recently,
a dabigatran-specific monoclonal antibody,
idarucizumab (Praxbind®), has been approved
for clinical use. The use of idarucizumab in
dabigatran reversal was demonstrated in an interim
analysis of the Reversal Effects of Idarucizumab on
Active Dabigatran Study (the RE-VERSE AD study)
[112]. The report included 90 patients (one-third
with ICH) with uncontrolled or life-threatening
bleeding, or requiring emergency surgical
procedures (<8 hours) [112]. Patients received
5 g of idarucizumab divided in two doses of
2.5 g at 15-minute intervals. Idarucizumab
reversed anticoagulation in 90 % of patients
within 10–30 minutes of drug infusion, as assessed
by the dilute thrombin time (TT) and ecarin
clotting time (ECT). Therefore, for patients with
dabigatran-related ICH, emergency treatment
should include discontinuation of the drug,
followed by two doses of 2.5 g idarucizumab IV at
15-minute intervals, if the last dose of dabigatran
was ingested within 3–5 half-lives or if renal
failure is present. In the occurrence of dabigatran
intoxication or renal failure, the use of hemodialysis
can be considered. If idarucizumab is not available,
or if the ICH is related to other direct thrombin
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inhibitors, emergency treatment should include
discontinuation of the drug followed by the
administration of activated PCC (50 U/kg) or a
four-factor PCC (50 U/kg), if the last dose of
drug was ingested within 3–5 terminal half-lives. If
the drug was taken more than 3–5 half-lives before
presentation, reversal in not indicated. In the case
of recent ingestion (within 2 hours), 50 g of
activated charcoal is recommended. The use of
rFVIIa or FFP in direct thrombin inhibitor-related
intracranial hemorrhage is not recommended.
e. rFVIIa in patients without coagulopathy. The use of
rFVIIa in noncoagulopathic patients has been
studied in multiple randomized trials and has been
shown to reduce hematoma growth but not to
improve patient survival or functional outcome.
Additionally, its use is associated with an increased
rate of arterial thromboembolic adverse events [113].
Currently, two clinical trials—the SPOTLIGHT trial
(ClinicalTrials.gov NCT01359202) and the STOP-IT
trial (ClinicalTrial.gov NCT0081088)—are underway
to clarify the role of rFVIIa in ICH patients with a
positive-spot sign. Current guidelines do not
recommend the use of rFVIIa in unselected
noncoagulopathic ICH patients [9].
f. Other anticoagulant agent reversal strategies are
summarized in Table 3.
Table 4 summarizes recent studies examining
hemostatic therapy, blood pressure management,
and the surgical approach to ICH.
Surgical treatment of spontaneous intracranial
hemorrhage
Supra-tentorial hemorrhage
The benefits of clot removal have been addressed in two
randomized trials. The Surgical Trial in Intracerebral
Hemorrhage (STICH) randomized 1033 patients with
supra-tentorial hemorrhage (lobar or ganglionic hematoma)
to early surgery (within 96 hours of ictus) versus standard
of care (i.e., medical management with delayed surgery if
necessary) [114]. No difference in favorable functional out-
come at 6 months was found (p = 0.414). However, the sub-
group of patients with superficial ICHs (lobar hemorrhage
within 1 cm of the cortical surface) who underwent surgery
had better outcomes. This result prompted a second trial,
STICH II, aiming at randomizing patients with superficial
lobar hematomas (10–100 ml) to early surgery versus med-
ical management with delayed surgery if necessary [115].
Patients with IVH or coma were excluded. STICH II found
no difference in mortality or severe disability with early
surgery (p = 0.37). Of note, patients with predicted poor
prognosis at enrollment (estimated according to a prog-
nostic model taking into account GCS, age, and ICH
volumes: 10 ×GCS − age− 0.64 × volume) were more likely
to have a favorable outcome with early surgery than with
initial conservative treatment (OR 0.49, p = 0.02). Such a
benefit with early surgery was not detected in the group of
patients with predicted good prognosis at enrollment
(OR 1.12, p = 0.57) [115].
Posterior fossa hemorrhage
Hemorrhage involving the posterior fossa (cerebellum or
brainstem; Fig. 2) can be associated with life-threatening
complications, such as acute hydrocephalus secondary
to fourth-ventricle compression and direct brainstem
compression and/or herniation through the foramen
magnum. Treatment strategies include posterior fossa
(suboccipital) decompressive craniectomy, external ven-
tricular drain (EVD) insertion or conservative manage-
ment. There is no randomized trial addressing the best
approach or timing to manage infra-tentorial hemorrhage
and the evidence available is based on class III studies.
Different protocols and algorithms have been published,
directing management strategies on the basis of GCS
and hematoma size [116], degree of fourth-ventricle
compression [117], or GCS and presence of hydro-
cephalus [118]. Patients with a GCS score of 14–15
and small hematomas (≤3 cm) can be treated conserva-
tively. In the case of neurological deterioration, hematoma
drainage ± craniectomy should be strongly considered. In
comatose patients without brainstem reflexes, formal
neurological determination of death should be considered.
Comatose patients with preserved brainstem reflexes
should be considered for emergency hematoma drainage
and suboccipital decompressive craniectomy. Insertion of
EVD alone for treatment of cerebellar occupying lesions
remains controversial because of the theoretical risk of up-
ward herniation and is not recommended by the AHA
guidelines [9]. However, management of recent cohorts of
patients with cerebellar infarcts showed that EVD alone is
a possible treatment, and can reduce the need for subocci-
pital decompressive craniectomy [119].
Intraventricular hemorrhage
IVH occurs in nearly half of ICH patients. Isolated IVH
(primary IVH) occurs rarely but more often is the result
of secondary extension of a parenchymal hematoma into
the ventricular system. The presence of blood in the
ventricles can interrupt the normal cerebrospinal fluid
(CSF) flow and cause obstructive (noncommunicating)
hydrocephalus and increased ICP. Placement of an EVD
to drain CSF and monitor ICP should therefore be
considered in patients with acute hydrocephalus/IVH
and GCS ≤ 8 or with signs of transtentorial herniation
[9]. A practical issue arises from the clot burden in
the ventricular system and the frequent obstruction of
ventricular drain. Techniques such as neuroendoscopy
or intraventricular thrombolysis (IVT) have been
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Table 4 Evidence-based summary
Study Design Intervention Results
Blood pressure management
Rapid Blood Pressure Reduction in Acute
Intracerebral Hemorrhage [152]
Prospective randomized, single-center study
Primary outcome: clinical deterioration (NIHSS
drop≥ 2 points) within the first 48 hours.
Hematoma enlargement at 24 hours was a
secondary endpoint
Eligible patients: acute spontaneous supra-
tentorial ICH within 8 hours of symptom onset
Exclusion criteria: history of head trauma; coma
with signs of herniation; coagulopathy;
MAP < 110 mmHg at presentation; secondary
ICH; surgical hematoma evacuation
Blood pressure targets: standard treatment
(MAP = 110–130 mmHg) vs aggressive BP
treatment (MAP < 110 mmHg)
Maximum interval from symptom onset to
treatment: 8 hours
Duration of treatment: 48 hours
Drugs used:
– Initially, intermittent labetalol infusions
(10–20 mg)
– If target blood pressure was not achieved, a
continuous infusion of nicardipine (5–15 mg/
hour) was started
– More severe cases were treated with
intravenous nicardipine from the onset (i.e.,
initial dose, 5 mg/hour followed by titration and
increases of 2.5 mg/hour every 5–15 minutes,
and no bolus)
– Most severe cases of hypertension were
treated with sodium nitroprusside infusion at
0.3 μg/kg/minute IV infusion and titrated every
few minutes to desired effect
21 patients in each group
Treatment was started on average 3.2 ± 2.2 hours
after symptom onset
Target blood pressure was achieved within
87.1 ± 59.6 minutes in the standard group and
163.5 ± 163.8 minutes in the aggressive BP
treatment group
No significant differences in early neurological
deterioration, hematoma and edema growth,
and clinical outcome at 90 days (mRS)
INTERACT trial [76] Open-label, multicenter, blinded outcome,
randomized trial; 44 hospital sites in Australia,
China, and South Korea
Primary outcome: proportional change in
hematoma volume at 24 hours
Eligible patients: spontaneous ICH and elevated
BP (≥2 measurements of 150–220 mmHg,
recorded ≥ 2 minutes apart)
Exclusion criteria: SBP > 220 mmHg or
hypertensive encephalopathy; severe cerebral
artery stenosis or renal failure; secondary ICH or
the use of a thrombolytic agent; ischemic stroke
within 30 days; GCS 3–5; significant prestroke
disability or medical illness; or early planned
decompressive neurosurgical intervention
Blood pressure targets: early intensive BP-
lowering strategy (target SBP = 140 mmHg
within 1 hour) vs standard approach (target
SBP =180 mmHg)
Maximum interval from symptom onset to
treatment: 6 hours
Duration of treatment: 7 days
Drugs used: treatment conducted with locally
available intravenous or oral BP-lowering agent,
each included (treatment group): furosemide
(35 %), urapidil (47 %), phentolamine (16 %), gly-
cerol trinitrate (10 %), labetalol (6 %), nicardipine
(5 %), hydralazine (3 %), metoprolol (1 %), nitrate
patch (3 %). It also included some oral agents
203 patients randomized to intensive BP
management vs 201 to standard guidelines-
based management
Trend toward lower hematoma growth at
24 hours in the intensive treatment group
(difference 22.6 %, 95 % CI 0.6–44.5 %, p = 0.04;
absolute difference in volume 1.7 ml, 95 % CI
0.5–3.9 ml, p = 0.13)
No excess of neurological deterioration, other
clinical outcomes, or adverse events
ATACH I trial [154] Phase I, dose-escalation, multicenter prospective
study
Eligible patients: spontaneous ICH with admission
SBP≥ 170 mmHg on two repeat measurements
at least 5 minutes apart. Symptom onset <
6 hours at the time to evaluation and initiation of
treatment with IV nicardipine
Primary outcomes: (1) Feasibility end point: SBP
reduction and maintenance in the respective
target range achieved (treatment success) or
not (failure); (2) Safety end points: (a) neurologic
deterioration (defined by a decline in the GCS
Blood pressure targets:
– Tier 1: SBP≥ 170 and < 200 mmHg
– Tier 2: SBP≥ 140 and < 170 mmHg
– Tier 3: SBP≥ 110 and < 140 mmHg
Maximum interval from symptom onset to
treatment: 6 hours
Duration of treatment: 18–24 hours
Drugs used: intravenous nicardipine infusion,
initiated at 5 mg/hour, and then increased by
2.5 mg every 15 minutes as needed, up to a
maximum of 15 mg/hour. Once the target SBP
was achieved, the infusion rate was decreased
60 patients enrolled (Tier 1 = 18; Tier 2 = 20;
Tier 3 = 22)
Nine patients in Tier 3 had treatment failure
Seven patients had neurologic deterioration
(one, two, and four in Tiers 1, 2, and 3,
respectively)
One subject in Tier 2 and three in Tier 3 had
serious adverse events; however, the safety-
stopping rule was not activated in any of the
tiers
These results confirmed the feasibility and safety












Table 4 Evidence-based summary (Continued)
score 2 or increase in NIHSS score 4 points not
explained by use of sedatives or hypnotics)
within 24 hours from treatment initiation; (b)
serious adverse events within 72 hours
by 1–3 mg/hour. If the SBP dropped below the
specified levels, infusion was reduced by
2.5 mg/hour every 15 minutes until the drug
was stopped
the based for the larger randomized ATACH II
trial
ICH ADAPT study [74] Multicenter, prospective, randomized, open-
label, with blinded evaluation study. A block
randomization design (six patients/block),
stratified by onset to treatment time (≤6 and
6–24 hours)
Eligible patients: spontaneous ICH diagnosed
<24 hours after onset and SBP >150 mmHg
Exclusion criteria: Secondary ICH (e.g., vascular
malformation), planned surgical resection, or
contraindications to CT perfusion (CTP; e.g.,
contrast allergy or renal impairment)
Primary end-point: difference in perihematoma
relative cerebral blood flow (CBF) between
treatment groups as assessed by CT perfusion
imaging 2 hours post randomization
Blood pressure targets: SBP target <150 mmHg
vs <180 mmHg to be achieved within 1 hour of
randomization
Drugs used: labetalol test dose: 10 mg bolus
over 1 minute. If SBP > target (150 or
180 mmHg) and heart rate (HR) > 55 bpm, the
bolus was repeated (10 mg bolus in 5 minutes).
10–20 mg IV push every 5 minutes until
SBP < target or HR < 55. Labetalol maximum
300 mg/24 hours
Hydralazine was used only if SBP persistently
> target, or if HR was below 55
Enalapril was used in the SBP < 150 mmHg
target group. It was considered in patients with
labile BP, who required repeated doses of
labetalol and/or hydralazine. 1.25 mg IV every
6 hours PRN
75 patients enrolled
Focal decreases in CBF and cerebral blood
volume within the perihematoma region
evident in all patients.
After adjustment for baseline intraparenchymal
hematoma volume and time to randomization,
perihematoma relative CBF not significantly
lower in patients randomized to SBP
< 150 mmHg (p = 0.18; absolute difference
0.03, 95 % CI –0.018 to 0.078)
INTERACT2 trial [71] International, multicenter, prospective,
randomized, open-treatment, blinded end-point
trial
Eligible patients: spontaneous ICH and elevated
BP (at least two SBP measurements of ≥150 and
≤220 mmHg, recorded 2 or more minutes
apart)
Exclusion criteria: structural cerebral cause for the
intracerebral hemorrhage; GCS 3–5; massive
hematoma with a poor prognosis; or early
planned surgery to evacuate the hematoma
Primary outcome: death or major disability
(mRS3–6 at 90 days)
Blood pressure targets: intensive treatment (SBP
<140 mmHg within 1 hour) vs guideline-
recommended treatment (SBP <180 mmHg)
Maximum interval from symptom onset to
treatment: 6 hours
Duration of treatment: 7 days
Drugs used: treatment conducted with locally
available intravenous BP-lowering agent, each
included (treatment group): alpha-adrenergic
antagonist (i.e.,
urapidil, 32.5 %), calcium-channel blocker (nicar-
dipine or nimodipine, 16.2 %), combined alpha-
and beta-blocker (labetalol, 14.4 %), nitroglycerin
(14.9 %),
furosemide (12.4 %), nitroprusside (12.1 %),
hydralazine (5.9 %)
2839 patients enrolled at 144 hospitals in 21
countries (n = 1403 early intensive treatment;
n = 1436 guideline-recommended treatment)
No statistically significant difference between
two groups in the rates of death or severe
disability (52 % vs 55.6 %; OR with intensive
treatment 0.87, 95 % CI 0.75–1.01, p = 0.06)
A pre-specified ordinal analysis of the mRS score
showed significantly lower scores with intensive
treatment (OR for greater disability 0.87, 95 % CI
0.77–1.00, p = 0.04)
ATACH 2 [77] International, multicenter, randomized, open
label trial
Eligible patients: ICH (volume, <60 cm3) and
GCS≥ 5
Exclusion criteria: structural cerebral cause for the
intracerebral hemorrhage; GCS 3–4; massive
hematoma with a poor prognosis; or early
planned surgery to evacuate the hematoma
Primary outcome: death or major disability (mRS
4–6 at 3 months)
Blood pressure targets: intensive treatment (SBP
110–139 mmHg within 2 hours) vs SBP between
140 and 179 mmHg)
Maximum interval from symptoms onset to
treatment: 4.5 hours
Duration of treatment: 24 hours
Drugs used: nicardipine IV, started at a dose of
5 mg per hour, and increased by 2.5 mg per
hour every 15 minutes (maximum dose of
15 mg per hour). Intravenous labetalol was
1000 patients enrolled at 110 sites in six
countries (n = 500 intensive treatment; n = 500
standard treatment)
No statistically significant difference in the rates
of death or disability (38.7 vs 37.7 %; intensive
vs standard treatment, respectively)
Relative risk, 1.04; 95 % CI 0.85–1.27; analysis
was adjusted for age, initial GCS score, and
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added as second-line agent, if the systolic blood
pressure target was not reached
The rate of renal adverse events within 7 days
was significantly higher in the intensive
treatment group (9.0 % vs 4.0 %, p = 0.002)
Intensive blood pressure reduction in
acute intracerebral hemorrhage: a meta-
analysis [155]
Systematic review and meta-analysis according
to PRISMA guidelines. Included available
randomized controlled trials that randomized
patients with acute ICH to either intensive or
guideline BP-reduction protocols at the time of
publication
Included four studies:
– Rapid Blood Pressure Reduction in Acute
Intracerebral Hemorrhage [152]
– INTERACT [76]
– ICH ADAPT [74]
– INTERACT2 [71]
3315 patients
Death rates were similar between the groups
(OR 5 1.01, 95 % CI 0.83–1.23, p ≤ 0.914)
Intensive BP-lowering treatment tended to be
associated with lower 3-month death or
dependency (mRS grades 3–6) compared with
guideline treatment (OR 5 0.87, 95 % CI 0.76–
1.01, p = 0.062)
No evidence of heterogeneity between
estimates (I2≤ 0 %, p≤ 0.723), or publication
bias in the funnel plots (p≤ 0.993, Egger
statistical test), was detected
Intensive BP reduction was also associated with
a greater attenuation of absolute hematoma
growth at 24 hours (standardized mean
difference ± SE: –0.110 ± 0.053, p = 0.038)
Hemostasis
FAST trial [153] Multicenter, randomized, double blinded,
placebo-controlled trial
Eligible patients: spontaneous ICH within 3 hours
of symptom onset
Exclusion criteria: GCS≤ 5; secondary ICH; known
use of anticoagulant therapy,
thrombocytopenia, or coagulopathy; acute
sepsis; crush injury; disseminated intravascular
coagulation; pregnancy; previous disability;
known recent thromboembolic disease
Primary outcome: death or severe disability (mRS
5–6 at 90 days)
Patients randomized to single intravenous dose
of rFVIIa (20 or 80 μg/kg) or placebo within
4 hours from stroke
841 patients (n = 268, placebo; n = 276, rFVII
20 μg/kg; n = 297, rFVII 80 μg/kg)
80 μg/kg of rFVIIa associated with significant
reduction in ICH expansion (mean estimated
increase in volume of ICH: 26 % placebo; 18 %
20 μg/kg; 11 % 80 μg/kg)
Despite the reduction in bleeding, no significant
difference in the proportion of patients with
poor outcome (24 % placebo; 26 % 20 μg/kg;
29 % 80 μg/kg)
More arterial thromboembolic events in the
group receiving rFVII 80 μg/kg versus placebo
(9 % vs 4 %, p = 0.04)
A meta-analysis of the efficacy and
safety of recombinant activated factor VII
for patients with acute intracerebral
hemorrhage without hemophilia [131]
Systematic review and meta-analysis Included five studies (one included traumatic
ICH patients):
– Safety and feasibility of recombinant factor
VIIa for acute intracerebral hemorrhage
– Recombinant activated factor VII for acute
intracerebral hemorrhage
– Recombinant activated factor VII for acute
intracerebral hemorrhage: US phase IIA trial
– Recombinant factor VIIA in traumatic
intracerebral hemorrhage: results of a dose-
escalation clinical trial
– Efficacy and safety of recombinant activated
factor VII for acute intracerebral hemorrhage
rFVIIa reduced the change in ICH volume
There was no significant difference in mortality,
mRS score or extended Glasgow Outcome Scale
(GOS-E) score in patients treated with rFVIIa or
placebo
There was a significant increase in arterial
thromboembolic adverse events in patients
treated with rFVIIa
There was an increase in deep vein thrombosis
in patients with spontaneous ICH and traumatic
ICH
PATCH trial [107] Multicenter, randomized, open-label, masked
end-point, parallel-group, phase 3 trial; 60
hospitals (36 Netherlands, 13 UK, 11 France)
Platelet transfusion (leukocyte-depleted, either
buffycoat derived or collected by apheresis) to
190 participants at 41 different sites enrolled
between February 2009 and October 2015 (97
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Eligible patients: nontraumatic supra-tentorial
ICH; GCS 8–15; antiplatelet therapy for at least
7 days preceding ICH; pre-ICH mRS 0–1
Exclusion criteria: epidural or subdural
hematoma; underlying aneurysm or
arteriovenous malformation; planned surgical
evacuation of ICH within 24 hours of admission;
IVH more than sedimentation in the posterior
horns of the lateral ventricles; previous adverse
reaction to platelet transfusion; vitamin k
antagonist use or knows coagulopathy;
thrombocytopenia (<100,000 cells/ml)
Primary outcome: difference in functional
outcome at 3 months after randomization
scored with mRS
be initiated within 6 hours of symptom onset
and 90 minutes of brain imaging
– COX inhibitor, with or without adenosine-
reuptake inhibitor: 1 platelet concentrate
(equivalent to 5 donor units)
– ADP receptor inhibitor, with or without
another antiplatelet drug: 2 platelet
concentrates
platelet transfusion and 93 assigned to standard
care without transfusion)
4 patients assigned to platelet transfusion did
not receive it; 2 participants assigned to
standard care alone received platelet transfusion
Primary outcome: higher odds of a shift towards
death or dependence at 3 months in the
platelet transfusion group (adjusted common
OR 2.05, 95 % CI 1.18–3.56, p = 0.0114)
Secondary analysis: more patients in the platelet
transfusion group with mRS 4–6 than those in
standard care group
In-hospital mortality: 24 (25 %) patients assigned
to platelet transfusion; 15 (16 %) patients
assigned to standard care alone
Pre-specified subgroup analyses (type of anti-
platelet therapy; country; hematoma volume):
no significant interaction
Serious adverse events: 40 (42 %) patients in
platelet transfusion group; 28 (29 %) patients in
standard care group
Surgical treatment
STICH [114] International, multicenter, prospective,
randomized trial
Eligible patients: spontaneous supra-tentorial ICH
within 72 hours; uncertainty about the benefits
of either treatment according to responsible
neurosurgeon
Exclusion criteria: secondary ICH; cerebellar
hemorrhage or extension of a supra-tentorial
hemorrhage into the brainstem; severe pre-
existing physical or mental disability or severe
comorbidities; surgery not undertaken within
24 hours of randomization
Primary outcome: death or disability using the
extended Glasgow Outcome Scale 6 months
after ictus
Patients randomized to early surgery
(hematoma evacuated within 24 hours of
randomization by the method of choice of the
responsible neurosurgeon, combined with the
best medical treatment) or to initial
conservative management (best medical
treatment; later surgical evacuation allowed in
case of neurological deterioration)
1033 patients from 83 centers in 27 countries
(n = 503 early surgery; n = 530 initial conservative
treatment)
Of the 468 patients randomized to early surgery
analyzed at 6 months, 122 (26 %) had a
favorable outcome compared with 118 (24 %)
of 496 patients randomized to initial
conservative treatment (OR 0.89, 95 % CI 0.66–
1.19, p = 0.414; absolute benefit 2.3 %; relative
benefit 10 %)
26 % of patients initially randomized to
conservative treatment underwent surgery after
an initial period of observation
Subgroup analysis of patients with lobar ICH
within 1 cm of the cortical surface who
underwent surgery had a statistically significant
increase in good outcomes compared with
similar subjects in the medical arm (8 %
absolute increase, p = 0.02)
STICH II [115] International, multicenter, prospective,
randomized, parallel group, pragmatic trial
Eligible patients: spontaneous lobar ICH, ≤1 cm
from the cortical surface of the brain, volume
between 10 and 100 ml; within 48 hours of
onset of ictus; best GCS motor score≥ 5 and
best GCS eye score ≥ 2
Exclusion criteria: secondary ICH; involvement of
basal ganglia, thalamic, cerebellar, or brainstem
Patients randomized to early surgery
(evacuation of hematoma within 12 hours of
randomization) or initial conservative treatment
(delayed evacuation permitted if judged
clinically appropriate)
601 patients from 78 centers in 27 countries
(n = 307 early surgery; n = 294 initial conservative
treatment)
Median time to craniotomy: 26 hours after
stroke onset
No difference in the primary outcome (absolute
difference 3.7 %, 95 % CI –4.3 to 11.6 %; OR
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regions; presence of IVH; severe pre-existing
physical or mental disability or severe
comorbidities
Primary outcome: prognosis-based favorable or
unfavorable outcome dichotomized from the
Extended Glasgow Outcome Scale at 6 months
after randomization
In the subgroup of patients with a poor
expected prognosis at enrollment (lower GCS,
greater age, and larger ICH volume), early
surgical intervention was associated with more
favorable outcome (OR 0.49, 95 % CI 0.26–0.92,
p = 0.02)
No advantage for surgery in the good
prognosis group (OR 1.2, 95 % CI 0.75–1.68,
p = 0.57)
Among patients in the initial conservative
treatment group, 21 % had surgery
BP blood pressure, CT computed tomography, GCS Glasgow Coma Scale, ICH intracerebral hemorrhage, mRS modified Rankin scale, NIHSS National Institutes of Health Stroke Scale, OR odds ratio, rFVIIa recombinant












investigated. The Clot Lysis Evaluation of Accelerated
Resolution of Intraventricular Hemorrhage (CLEAR-IVH)
trial demonstrated that the use of low-dose recombinant
tissue plasminogen activator (r-tPA) had an acceptable
safety profile in patients with IVH, as well as being benefi-
cial in accelerating the removal of clot from the ventricu-
lar system [120]. The phase III CLEAR-IVH III trial [121],
comparing the use of EVD combined with intraventricular
injection of r-tPA to EVD plus intraventricular injection of
normal saline (placebo) for the treatment of IVH, has been
completed (500 subjects enrolled from 73 sites between
2009 and 2014) and preliminary results have been pre-
sented recently at the International Stroke Conference
(ISC) 2016. The primary outcome of dichotomized mRS
0–3 vs 4–6 at 180 days was not significantly different be-
tween the two groups, but the treatment was associated
with a 10 % reduction in mortality without increasing the
number of patients in a vegetative state or with severe dis-
ability. The CLEAR-IVH III researchers also reported that
patients with larger clots and more than 20 ml of blood
removed showed a significant improvement in functional
outcome. In terms of safety, symptomatic bleeding was
not more frequent in the alteplase group, and it was asso-
ciated with a reduction in bacterial ventriculitis (7 % vs
12 %, p = 0.05) (official publication of results awaited)
[122]. Li et al. [123], in a systematic review and meta-
analysis of 11 studies including five RCTs (680 patients),
found that the neuroendoscopy + EVD approach seemed
to be better than the EVD + IVT approach in terms of
mortality, effective hematoma evacuation rate, good
functional outcome, and the ventriculoperitoneal shunt
dependence rate.
Minimally invasive surgery
New approaches for hematoma drainage have emerged
in the last decade, including stereotactic aspiration of
clot ± thrombolysis or endoscopic procedures. Overall,
minimally invasive surgery has been associated with im-
provement in clot removal compared with standard sur-
gical techniques [124, 125]. Cho et al. [126] compared
three approaches (neuroendoscopy vs stereotactic aspir-
ation vs craniotomy) in a randomized trial of 90 nonco-
matose patients with ganglionic hematomas. There was
no difference in mortality but patients treated endoscop-
ically had better functional outcomes within 6 months of
surgery as assessed by functional independence measure
score, Barthel index score, and muscle power. A recent
systematic review and meta-analysis showed that death
or dependence is significant reduced by minimally invasive
surgery when compared with medical management or
conventional craniotomy [127]. The Minimally Invasive
Surgery Plus rt-PA for ICH Evacuation Phase III (MISTIE
III) trial (ClinicalTrials.gov NCT01827046) is currently
assessing the usefulness of stereotactic catheter placement
into intraparenchymal hematomas followed by direct in-
jection of r-tPA for 3 days and aspiration.
Quality in acute stroke care
There is evidence for the benefit of stroke units [70]
with a significant positive impact on long-term outcome
(i.e., decreased morbidity and mortality). Medical compli-
cations such as fever, hyperglycemia, VTE, and dysphagia
are still not universally optimally managed [128]. Hyper-
thermia (temperature > 37.5 °C), hyperglycemia, and
dysphagia occur in 20–50 %, up to 50 %, and between
37 and 78 % of patients, in the first days after the
stroke, respectively.
A. Hyperglycemia is common in patients presenting
with ICH and is associated with poor outcomes
(hematoma expansion, increased edema, death, or
severe disability) [129–132]. The optimal glucose
level and the best hyperglycemia management
strategy remain to be elucidated. However, both
hypoglycemia (<70 mg/dl or < 3.9 mmol/L) and
hyperglycemia (>180 mg/dl or 10 mmol/L) should
be avoided [9].
B. Temperature. Fever is a common occurrence
affecting between 30 and 50 % of patients with ICH,
and is independently associated with poor outcomes
[133, 134]. The presence of IVH is the main risk
factor for fever not explained by infections or drugs
[135]. There are no available data from RCTs
addressing the role of induced normothermia after
ICH. At this point, the suggested goal is to keep a
core temperature below 37.5–38 °C [9]. One pilot
study (iCOOL1) randomized 20 patients with acute
stroke to induced normothermia (cold saline
infusion (4 °C, 2 L at 4 L/hour) vs nasopharyngeal
cooling (60 L/minute for 1 hour)). A high incidence
of serious adverse events (seven in total) was reported,
suggesting that safety of cooling in acute stroke
patients awaits evaluation in future trials [136].
C. Prevention of VTE. Patients with ICH are
considered at high risk of VTE, reported to be up to 4-
fold higher than in patients with ischemic stroke [137].
Initial prophylaxis utilizes intermittent pneumatic
compression devices to be positioned at the time of
hospital admission (Strong recommendation and
high-quality evidence) [138, 139], followed by
pharmacological prophylaxis with UFH or LMWH,
initiated after documented cessation of bleeding by
imaging [140]. This is often considered to be 24–48
hours from the initial hemorrhage [139].
D. Dysphagia is common after stroke, and its reported
incidence varies from 37 to 78 %, depending on the
technique used for detection [141]. Dysphagia is
associated with increased risk for pneumonia/
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pneumonitis (RR 3.17, 95 % CI 2.07-4.87) [141].
Occurrence of aspiration pneumonia can be reduced
by formal dysphagia screening (e.g., water swallow
test) from 5.4 % to 2.4 % (3 % absolute risk
reduction) [142]. According to the AHA/ASA
guidelines, “a formal screening procedure for
dysphagia should be performed in all patients before
the initiation of oral intake to reduce the risk of
pneumonia” (Class I; Level of Evidence B) [9].
E. Anemia. Hemoglobin levels on admission and nadir
levels seem to be associated with outcome after ICH
[143, 144]. However, there is currently no universally
accepted ideal hemoglobin level in this population.
F. Seizure prophylaxis. Seizure frequency has been
reported between 8.1 and 10.6 % in patients with
ICH, with status epilepticus occurring in 1–2 % of
patients [9]. Lobar hemorrhages are independent
predictor of early and late seizures (i.e., occurring
more than 2 weeks after ictus). However, prophylactic
use of anticonvulsants in ICH patients is associated
with worse outcomes. Phenytoin has been associated
with increased side effects and worse outcomes [145].
The current AHA ICH guidelines do not recommend
the use of prophylactic anticonvulsants [9].
Continuous EEG has become a monitor that is
used in the management of patients with ICH.
Claassen et al. [146] reviewed the records of 102
consecutive patients who underwent continuous
EEG monitoring after ICH. They found that one-third
of ICH patients developed seizures, with more than
half having only electroencephalographic evidence of
seizures. They also found a correlation between
electroencephalographic seizures and expanding
hemorrhages, and also between periodic discharges in
patients with cortical ICH and poorer outcomes
[146]. Patients with ICH presenting with a decreased
level of consciousness out of proportion to the clinical
expected level of neurologic impairment may benefit
from continuous EEG monitoring, which can be used
to trigger or modify therapy [9].
Management of increased ICP is a topic beyond the
scope of this review, and we refer to very informative ar-
ticles published recently [147]. In general, ICP manage-
ment strategies include: head of bed elevation between
30 and 45°, CSF drainage through EVD, analgesia and
sedation, normocapneic ventilation, and administration
of hypertonic solutions (e.g., hypertonic saline or manni-
tol). In refractory cases, hypothermia, barbiturates, or
decompressive craniectomy can be attempted [147].
Challenges in prognostication
Several clinical ICH grading scales have been published
with the ultimate goal of risk stratification and
prognostication [68]. However, a confounder in the ac-
curacy of these scales is the impact of withholding or
withdrawal of life support (WOLS). Most ICH patients
die in the acute phase because of WOLS [148, 149]; es-
pecially in patients with a high ICH score, WOLS is as-
sociated with early death [148, 149]. Diringer et al. [150]
showed in a large series of more than 2000 mechanically
ventilated patients admitted to a neuroscience ICU that
older or comatose patients were more likely to have their
life support withdrawn. Because of the uncertainty in
prognostication in the early phase, early aggressive man-
agement is recommended after ICH, and treatment limita-
tions should not be based solely on prognostic models [9].
Conclusion
Spontaneous ICH is a neurological emergency associated
with high mortality and morbidity. Key management
issues include prompt etiologic diagnosis, reversal of
anticoagulation, consideration of surgical management,
and control of blood pressure. The clinical scenario and
local practice will influence choice of therapeutic environ-
ment. As of March 2016, there were 581 ClinicalTrials.gov
registered trials evaluating therapeutic opportunities in
ICH. Early prognostication should not be attempted ex-
cept when clear signs of nonconfounded irreversible
brain damage are present, such as an absence of brain
stem reflexes.
Additional file
Additional file 1: Table S1. Etiology of spontaneous ICH. Table S2.
Initial management. Table S3. Composition of some four-factor PCCs.
Table S4. Ongoing studies on ICH management, and Table S5.
Hematoma expansion scores. (DOCX 28 kb)
Abbreviations
AAICH, anticoagulant-associated intracerebral hemorrhage; APT, antiplatelet
therapy; ATACH, Antihypertensive Treatment of Acute Cerebral Hemorrhage;
BP, blood pressure; CBF, cerebral blood flow; CMRO2, cerebral metabolic rate
of oxygen; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; CT,
computed tomography; CTA, computed tomography angiography; DSA,
digital subtraction angiography; ED, emergency department; EVD, external
ventricular drain; FFP, fresh frozen plasma; GCS, Glasgow Coma Scale;
ICH, intracerebral hemorrhage; ICP, intracranial pressure; INR, International
Normalized Ratio; IVH, intraventricular hemorrhage; IVT, intraventricular
thrombolysis; MRI, magnetic resonance imaging; mRS, modified Rankin
Scale; NIHSS, National Institutes of Health Stroke Scale; OEFmax, maximum
oxygen extraction fraction; OR, odds ratio; PCC, prothrombin complex
concentrate; rFVIIa, recombinant activated factor VII; r-tPA, recombinant
tissue plasminogen activator; SBP, systolic blood pressure; VTE, venous
thromboembolism; WOLS, withdrawal of life support
Acknowledgements
This work was supported by generous funding provided by the Bitove
Foundation.
Authors’ contributions
DT-P, FGZ, AG, AD, SA, and ALdOM formed the conceptual framework for
this article. AG and ALdOM conducted the literature search. ALdOM, FGZ,
and AG were responsible for the tables. ALdOM and AG were responsible for
the figures. TRM, AD, RLM, and SA provided critical support and gave
de Oliveira Manoel et al. Critical Care  (2016) 20:272 Page 25 of 29
important scientific feedback on the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Medical Imaging, Interventional Neuroradiology, St. Michael’s
Hospital—University of Toronto, 30 Bond Street, Toronto, ON M5B 1W8,
Canada. 2Department of Critical Care Medicine, Trauma & Neurosurgical
Intensive Care Unit, St. Michael’s Hospital—University of Toronto, Toronto,
ON, Canada. 3Neuroscience Research Program, Keenan Research Centre for
Biomedical Science of St. Michael’s Hospital, Toronto, ON, Canada.
4Department of Medicine, Division of Respirology (Critical Care), University
Health Network, Toronto, ON, Canada. 5Interdepartmental Division of Critical
Care Medicine and Department of Medicine, University of Toronto, Toronto,
ON, Canada. 6Intensive Care Unit, Hospital das Clínicas, Universidade de São
Paulo, São Paulo, Brazil. 7Intensive Care Unit, Hospital Alemão Oswaldo Cruz,
São Paulo, Brazil. 8Medical Intensive Care Unit, Department of Pulmonary,
Allergy, and Critical Care, Respiratory Institute, Cleveland Clinic, Cleveland,
OH, USA. 9Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University, Cleveland, OH, USA. 10Department of Surgery, Division of
Neurosurgery, St. Michael’s Hospital—University of Toronto, Toronto, ON,
Canada. 11Department of Anesthesiology, St. Michael’s Hospital—University
of Toronto, Toronto, ON, Canada.
References
1. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral
haemorrhage. Lancet Neurol. 2006;5:53–63.
2. Zheng H, Chen C, Zhang J, Hu Z. Mechanism and Therapy of Brain Edema
after Intracerebral Hemorrhage. Cerebrovasc Dis. 2016;42:155–169.
3. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet.
2009;373(9675):1632–44. doi:10.1016/S0140-6736(09)60371-8.
4. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ.
Incidence, case fatality, and functional outcome of intracerebral
haemorrhage over time, according to age, sex, and ethnic origin: a
systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167–76.
doi:10.1016/S1474-4422(09)70340-0.
5. Balami JS, Buchan AM. Complications of intracerebral haemorrhage. Lancet
Neurol. 2011;11(1):101–18. doi:10.1016/S1474-4422(11)70264-2.
6. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional
burden of first-ever ischaemic and haemorrhagic stroke during 1990–
2010: findings from the Global Burden of Disease Study 2010. Lancet
Glob Health. 2013;1(5):e259–81. doi:10.1016/S2214-109X(13)70089-5.
7. Krishnamurthi RV, Moran AE, Forouzanfar MH, et al. The global burden of
hemorrhagic stroke. Global Heart. 2014;9(1):101–6. doi:10.1016/j.gheart.2014.01.003.
8. Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival
of intracerebral hemorrhage in a population-based registry. Stroke.
2009;40(2):394–9. doi:10.1161/STROKEAHA.108.523209.
9. Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the
Management of Spontaneous Intracerebral Hemorrhage: A Guideline for
Healthcare Professionals from the American Heart Association/American
Stroke Association. Stroke. 2015;46(7):2032–60. doi:10.1161/STR.
0000000000000069.
10. Rincon F, Mayer SA. The epidemiology of intracerebral hemorrhage in the
United States from 1979 to 2008. Neurocrit Care. 2012;19(1):95–102.
doi:10.1007/s12028-012-9793-y.
11. Becker KJ, Baxter AB, Cohen WA, et al. Withdrawal of support in intracerebral
hemorrhage may lead to self-fulfilling prophecies. Neurology. 2001;56(6):766–72.
12. Gattellari M, Goumas C, Worthington J. Declining rates of fatal and nonfatal
intracerebral hemorrhage: epidemiological trends in Australia. J Am Heart
Assoc. 2014;3(6):e001161. doi:10.1161/JAHA.114.001161.
13. Koton S, Schneider ALC, Rosamond WD, et al. Stroke incidence and
mortality trends in US communities, 1987 to 2011. JAMA. 2014;312(3):259–68.
doi:10.1001/jama.2014.7692.
14. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-
associated intracerebral hemorrhage. Neurology. 2007;68(2):116–21.
doi:10.1212/01.wnl.0000250340.05202.8b.
15. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis
of efficacy and safety of new oral anticoagulants (dabigatran,
rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Am J Cardiol. 2012;110(3):453–60. doi:10.1016/j.amjcard.2012.03.049.
16. Abu-Zeid HAH. Prognostic factors in the survival of 1,484 stroke cases
observed for 30 to 48 months. Arch Neurol. 1978;35(3):121. doi:10.1001/
archneur.1978.00500270003001.
17. Carpenter AM, Singh IP, Gandhi CD, Prestigiacomo CJ. Genetic risk factors
for spontaneous intracerebral haemorrhage. Nat Publ Group. 2015;12(1):40–9.
doi:10.1038/nrneurol.2015.226.
18. Martini SR, Flaherty ML, Brown WM, et al. Risk factors for intracerebral
hemorrhage differ according to hemorrhage location. Neurology.
2013;79(23):2275–82. doi:10.1212/WNL.0b013e318276896f.
19. Flaherty ML, Woo D, Haverbusch M, et al. Racial variations in location and
risk of intracerebral hemorrhage. Stroke. 2005;36(5):934–7. doi:10.1161/01.
STR.0000160756.72109.95.
20. Ariesen MJ, Claus SP, Rinkel GJE, Algra A. Risk factors for intracerebral
hemorrhage in the general population: a systematic review. Stroke.
2003;34(8):2060–5. doi:10.1161/01.STR.0000080678.09344.8D.
21. Sturgeon JD, Folsom AR, Longstreth WT, Shahar E, Rosamond WD, Cushman
M. Risk factors for intracerebral hemorrhage in a pooled prospective study.
Stroke. 2007;38(10):2718–25. doi:10.1161/STROKEAHA.107.487090.
22. Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke.
2015;17(1):17–30. doi:10.5853/jos.2015.17.1.17.
23. McCarron MO, Nicoll JA. Apolipoprotein E genotype and cerebral amyloid
angiopathy-related hemorrhage. Ann N Y Acad Sci. 2000;903:176–9.
24. Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin,
hematoma expansion, and outcome of intracerebral hemorrhage.
Neurology. 2004;63(6):1059–64.
25. Howard G, Cushman M, Howard VJ, et al. Risk factors for intracerebral
hemorrhage: the REasons for geographic and racial differences in stroke
(REGARDS) study. Stroke. 2013;44(5):1282–7. doi:10.1161/STROKEAHA.111.000529.
26. Jauch EC, Pineda JA, Claude HJ. Emergency neurological life support:
intracerebral hemorrhage. Neurocrit Care. 2015;23 Suppl 2:83–93.
doi:10.1007/s12028-015-0167-0.
27. Maas MB, Berman MD, Guth JC, Liotta EM, Prabhakaran S, Naidech AM.
Neurochecks as a biomarker of the temporal profile and clinical impact of
neurologic changes after intracerebral hemorrhage. J Stroke Cerebrovasc
Dis. 2015;24(9):2026–31. doi:10.1016/j.jstrokecerebrovasdis.2015.04.045.
28. Maas MB, Rosenberg NF, Kosteva AR, et al. Surveillance neuroimaging
and neurologic examinations affect care for intracerebral hemorrhage.
Neurology. 2013;81(2):107–12. doi:10.1212/WNL.0b013e31829a33e4.
29. Runchey S, McGee S. Does this patient have a hemorrhagic stroke?: clinical
findings distinguishing hemorrhagic stroke from ischemic stroke. JAMA.
2010;303(22):2280–6. doi:10.1001/jama.2010.754.
30. Alobeidi F, Aviv RI. Emergency imaging of intracerebral haemorrhage.
Front Neurol Neurosci. 2015;37:13–26. doi:10.1159/000437110.
31. Zhu XLX, Chan MSM, Poon WSW. Spontaneous intracranial hemorrhage:
which patients need diagnostic cerebral angiography? A prospective
study of 206 cases and review of the literature. Stroke. 1997;28(7):1406–9.
doi:10.1161/01.STR.28.7.1406.
32. Bekelis K, Desai A, Zhao W, et al. Computed tomography angiography:
improving diagnostic yield and cost effectiveness in the initial
evaluation of spontaneous nonsubarachnoid intracerebral hemorrhage.
J Neurosurg. 2012;117(4):761–6. doi:10.3171/2012.7.JNS12281.
33. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med.
2005;352(17):1791–8. doi:10.1056/NEJMra042354.
34. Delgado Almandoz JE, Schaefer PW, Forero NP, Falla JR, Gonzalez RG, Romero
JM. Diagnostic accuracy and yield of multidetector CT angiography in the
evaluation of spontaneous intraparenchymal cerebral hemorrhage. Am J
Neuroradiol. 2009;30(6):1213–21. doi:10.3174/ajnr.A1546.
35. Yeung R, Ahmad T, Aviv RI, de Tilly LN, Fox AJ, Symons SP. Comparison of CTA
to DSA in determining the etiology of spontaneous ICH. Can J Neurol Sci. 2009;
36(2):176–80.
36. Wong GKC, Siu DYW, Abrigo JM, et al. Computed tomographic angiography
and venography for young or nonhypertensive patients with acute
spontaneous intracerebral hemorrhage. Stroke. 2011;42(1):211–3.
doi:10.1161/STROKEAHA.110.592337.
37. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of
intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day
mortality. Stroke. 1993;24(7):987–93.
de Oliveira Manoel et al. Critical Care  (2016) 20:272 Page 26 of 29
38. Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC, Tuhrim S.
The ICH score: a simple, reliable grading scale for intracerebral hemorrhage.
Stroke. 2001;32(4):891–7. doi:10.1161/01.STR.32.4.891.
39. Webb AJS, Ullman NL, Morgan TC, et al. Accuracy of the ABC/2 score for
intracerebral hemorrhage: systematic review and analysis of MISTIE, CLEAR-IVH,
and CLEAR III. Stroke. 2015;46(9):2470–6. doi:10.1161/STROKEAHA.114.007343.
40. Kothari RU, Brott T, Broderick JP, et al. The ABCs of measuring intracerebral
hemorrhage volumes. Stroke. 1996;27(8):1304–5. doi:10.1161/01.STR.27.8.1304.
41. Hallevi H, Albright KC, Aronowski J, et al. Intraventricular hemorrhage:
anatomic relationships and clinical implications. Neurology. 2008;70(11):848–52.
doi:10.1212/01.wnl.0000304930.47751.75.
42. Bhattathiri PS, Gregson B, Prasad KSM, Mendelow AD, STICH Investigators.
Intraventricular hemorrhage and hydrocephalus after spontaneous intracerebral
hemorrhage: results from the STICH trial. Acta Neurochir Suppl. 2006;96:65–8.
43. Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular
hemorrhage in patients with spontaneous intracerebral hemorrhage: risk
factors, clinical impact, and effect of hemostatic therapy with recombinant
activated factor VII. Neurosurgery. 2006;59(4):767–73. doi:10.1227/01.NEU.
0000232837.34992.32. discussion773–4.
44. Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in
noncomatose patients with supratentorial intracerebral hemorrhage.
Neurology. 1994;44(8):1379–84.
45. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients
with intracerebral hemorrhage. Stroke. 1997;28(1):1–5. doi:10.1161/01.STR.28.1.1.
46. Specogna AV, Turin TC, Patten SB, Hill MD. Factors associated with early
deterioration after spontaneous intracerebral hemorrhage: a systematic review and
meta-analysis. PLoS One. 2014;9(5):e96743–3. doi:10.1371/journal.pone.0096743.
47. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant
of mortality and poor outcome after intracerebral hemorrhage. Neurology.
2006;66(8):1175–81. doi:10.1212/01.wnl.0000208408.98482.99.
48. Dowlatshahi D, Demchuk AM, Flaherty ML, et al. Defining hematoma
expansion in intracerebral hemorrhage: relationship with patient outcomes.
Neurology. 2011;76(14):1238–44. doi:10.1212/WNL.0b013e3182143317.
49. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of
spontaneous intracerebral hemorrhage. Incidence and time course. Stroke.
1996;27(10):1783–7.
50. Brouwers HB, Chang Y, Falcone GJ, et al. Predicting hematoma expansion
after primary intracerebral hemorrhage. JAMA Neurol. 2014;71(2):158–64.
doi:10.1001/jamaneurol.2013.5433.
51. Wang X, Arima H, Al-Shahi Salman R, et al. Clinical prediction algorithm
(BRAIN) to determine risk of hematoma growth in acute intracerebral
hemorrhage. Stroke. 2015;46(2):376–81. doi:10.1161/STROKEAHA.114.006910.
52. Huynh TJ, Aviv RI, Dowlatshahi D, Gladstone DJ. Validation of the 9-point
and 24-point hematoma expansion prediction scores and derivation of the
PREDICT A/B scores. Stroke. 2015. doi:10.1161/STROKEAHA.115.009893/-/DC1.
53. Du F-Z, Jiang R, Gu M, He C, Guan J. The accuracy of spot sign in predicting
hematoma expansion after intracerebral hemorrhage: a systematic review
and meta-analysis. PLoS One. 2014;9(12):e115777–7. doi:10.1371/journal.
pone.0115777.
54. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T, Cohen WA.
Extravasation of radiographic contrast is an independent predictor of death
in primary intracerebral hemorrhage. Stroke. 1999;30(10):2025–32.
55. Murai Y, Takagi R, Ikeda Y, Yamamoto Y, Teramoto A. Three-dimensional
computerized tomography angiography in patients with hyperacute intracerebral
hemorrhage. J Neurosurg. 1999;91(3):424–31. doi:10.3171/jns.1999.91.3.0424.
56. Goldstein JN, Fazen LE, Snider R, et al. Contrast extravasation on CT
angiography predicts hematoma expansion in intracerebral hemorrhage.
Neurology. 2007;68(12):889–94. doi:10.1212/01.wnl.0000257087.22852.21.
57. Wada R, Aviv RI, Fox AJ, et al. CT Angiography “spot sign” predicts
hematoma expansion in acute intracerebral hemorrhage. Stroke.
2007;38(4):1257–62. doi:10.1161/01.STR.0000259633.59404.f3.
58. Ederies A, Demchuk A, Chia T, et al. Postcontrast CT extravasation is
associated with hematoma expansion in CTA spot negative patients. Stroke.
2009;40(5):1672–6. doi:10.1161/STROKEAHA.108.541201.
59. Hallevi H, Abraham AT, Barreto AD, Grotta JC, Savitz SI. The spot sign in
intracerebral hemorrhage: the importance of looking for contrast
extravasation. Cerebrovasc Dis. 2010;29(3):217–20. doi:10.1159/000267842.
60. Brouwers HB, Goldstein JN, Romero JM, Rosand J. Clinical applications
of the computed tomography angiography spot sign in acute
intracerebral hemorrhage: a review. Stroke. 2012;43(12):3427–32.
doi:10.1161/STROKEAHA.112.664003.
61. Tsukabe A, Watanabe Y, Tanaka H, et al. Prevalence and diagnostic
performance of computed tomography angiography spot sign for
intracerebral hematoma expansion depend on scan timing. Neuroradiology.
2014;56(12):1039–45. doi:10.1007/s00234-014-1430-3.
62. Almandoz JED, Yoo AJ, Stone MJ, et al. Systematic characterization of the
computed tomography angiography spot sign in primary intracerebral
hemorrhage identifies patients at highest risk for hematoma expansion:
the spot sign score. Stroke. 2009;40(9):2994–3000. doi:10.1161/
STROKEAHA.109.554667.
63. Delgado Almandoz JE, Yoo AJ, Stone MJ, et al. The spot sign score in
primary intracerebral hemorrhage identifies patients at highest risk of
in-hospital mortality and poor outcome among survivors. Stroke.
2009;41(1):54–60. doi:10.1161/STROKEAHA.109.565382.
64. Rodriguez-Luna D, Dowlatshahi D, Aviv RI, et al. Venous phase of computed
tomography angiography increases spot sign detection, but intracerebral
hemorrhage expansion is greater in spot signs detected in arterial phase.
Stroke. 2014;45(3):734–9. doi:10.1161/STROKEAHA.113.003007.
65. Evans A, Demchuk A, Symons SP, et al. The spot sign is more common in
the absence of multiple prior microbleeds. Stroke. 2010;41(10):2210–7.
doi:10.1161/STROKEAHA.110.593970.
66. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D. Prediction of haematoma
growth and outcome in patients with intracerebral haemorrhage using the
CT-angiography spot sign (PREDICT): a prospective observational study.
Lancet Neurol. 2012;11(4):307–14. doi:10.1016/s1474-4422(12)70038-8.
67. Goldstein JN, Brouwers HB, Romero JM, et al. SCORE-IT: the Spot Sign score
in restricting ICH growth─an Atach-II ancillary study. J Vasc Interv Neurol.
2012;5 Suppl:20.
68. Hwang BY, Appelboom G, Kellner CP, et al. Clinical grading scales in
intracerebral hemorrhage. Neurocrit Care. 2010;13(1):141–51. doi:10.1007/
s12028-010-9382-x.
69. Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical
intensive care unit is associated with reduced mortality rate after
intracerebral hemorrhage. Crit Care Med. 2001;29(3):635–40.
70. Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit)
care for stroke. Cochrane Database Syst Rev. 2013;9:CD000197.
doi:10.1002/14651858.CD000197.pub3.
71. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering
in patients with acute intracerebral hemorrhage. N Engl J Med.
2013;368(25):2355–65. doi:10.1056/NEJMoa1214609.
72. Terént A, Asplund K, Farahmand B, et al. Stroke unit care revisited: who
benefits the most? A cohort study of 105,043 patients in Riks-Stroke, the
Swedish Stroke Register. J Neurol Neurosurg Psychiatry. 2009;80(8):881–7.
doi:10.1136/jnnp.2008.169102.
73. Zazulia ARA, Diringer MNM, Videen TOT, et al. Hypoperfusion without
ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow
Metab. 2001;21(7):804–10. doi:10.1097/00004647-200107000-00005.
74. Butcher KS, Jeerakathil T, Hill M, et al. The Intracerebral Hemorrhage
Acutely Decreasing Arterial Pressure Trial. Stroke. 2013;44(3):620–6.
doi:10.1161/STROKEAHA.111.000188.
75. Kate MP, Hansen MB, Mouridsen K, et al. Blood pressure reduction does not
reduce perihematoma oxygenation: a CT perfusion study. J Cereb Blood
Flow Metab. 2013;34(1):81–6. doi:10.1038/jcbfm.2013.164.
76. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction
in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial.
Lancet Neurol. 2008;7(5):391–9. doi:10.1016/S1474-4422(08)70069-3.
77. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering
in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016.
doi:10.1056/NEJMoa1603460. [Epub ahead of print]
78. Prabhakaran S, Naidech AM. Ischemic brain injury after intracerebral
hemorrhage: a critical review. Stroke. 2012;43(8):2258–63. doi:10.1161/
STROKEAHA.112.655910.
79. Ortega-Gutierrez S, Thomas J, Reccius A, et al. Effectiveness and safety of
nicardipine and labetalol infusion for blood pressure management in
patients with intracerebral and subarachnoid hemorrhage. Neurocrit Care.
2013;18(1):13–9. doi:10.1007/s12028-012-9782-1.
80. Liu-DeRyke X, Levy PD, Parker D, Coplin W, Rhoney DH. A prospective
evaluation of labetalol versus nicardipine for blood pressure management
in patients with acute stroke. Neurocrit Care. 2013;19(1):41–7. doi:10.1007/
s12028-013-9863-9.
81. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The
effect of warfarin and intensity of anticoagulation on outcome of
de Oliveira Manoel et al. Critical Care  (2016) 20:272 Page 27 of 29
intracerebral hemorrhage. Arch Intern Med. 2004;164(8):880–4.
doi:10.1001/archinte.164.8.880.
82. Hart RG, Boop BS, Anderson DC. Oral Anticoagulants and intracranial
hemorrhage: facts and hypotheses. Stroke. 1995;26(8):1471–7.
doi:10.1161/01.STR.26.8.1471.
83. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with
oral anticoagulant therapy: current practices and unresolved questions.
Stroke. 2006;37(1):256–62. doi:10.1161/01.STR.0000196989.09900.f8.
84. Wintzen AR, de Jonge H, Loeliger EA, Bots GT. The risk of intracerebral
hemorrhage during oral anticoagulant treatment: a population study. Ann
Neurol. 1984;16(5):553–8. doi:10.1002/ana.410160505.
85. Hylek EM. Risk factors for intracranial hemorrhage in outpatients taking
warfarin. Ann Intern Med. 1994;120(11):897–902. doi:10.7326/0003-4819-120-11-
199406010-00001.
86. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual,
or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial
fibrillation. Arch Intern Med. 2010;170:1433–41.
87. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-
friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients
with atrial fibrillation. Chest. 2010;138(5):1093–100. doi:10.1378/chest.10-0134.
88. Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger
intracerebral hematomas. Neurology. 2008;71(14):1084–9. doi:10.1212/01.
wnl.0000326895.58992.27.
89. Flaherty ML, Haverbusch M, Sekar P, et al. Location and outcome of
anticoagulant-associated intracerebral hemorrhage. Neurocrit Care.
2006;5(3):197–201. doi:10.1385/NCC:5:3:197.
90. Frontera JA, Iii JJL, Rabinstein AA, et al. Guideline for Reversal of
Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare
Professionals from the Neurocritical Care Society and Society of Critical
Care Medicine. Neurocrit Care. 2016;24(1):6–46. doi:10.1007/s12028-015-
0222-x.
91. Vigué B, Ract C, Tremey B, et al. Ultra-rapid management of oral
anticoagulant therapy-related surgical intracranial hemorrhage. Intensive
Care Med. 2007;33(4):721–5. doi:10.1007/s00134-007-0528-z.
92. Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin
complex concentrate for warfarin reversal: does it matter? Thromb Res.
2012;130(6):833–40. doi:10.1016/j.thromres.2012.10.001.
93. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R.
Suboptimal effect of a three-factor prothrombin complex concentrate
(Profilnine-SD) in correcting supratherapeutic international normalized
ratio due to warfarin overdose. Transfusion. 2009;49(6):1171–7.
doi:10.1111/j.1537-2995.2008.02080.x.
94. Tazarourte K, Riou B, Tremey B, Samama C-M, Vicaut E, Vigué B. Guideline-
concordant administration of prothrombin complex concentrate and
vitamin K is associated with decreased mortality in patients with severe
bleeding under vitamin K antagonist treatment (EPAHK study). Crit Care.
2014;18(2):R81–1. doi:10.1186/cc13843.
95. Pernod G, Godiér A, Gozalo C, Tremey B, Sié P. French clinical practice
guidelines on the management of patients on vitamin K antagonists in
at-risk situations (overdose, risk of bleeding, and active bleeding).
Thromb Res. 2010;126(3):e167–74. doi:10.1016/j.thromres.2010.06.017.
96. Hickey M, Gatien M, Taljaard M, Aujnarain A, Giulivi A, Perry JJ.
Outcomes of urgent warfarin reversal with frozen plasma versus
prothrombin complex concentrate in the emergency department.
Circulation. 2013;128(4):360–4. doi:10.1161/CIRCULATIONAHA.113.001875.
97. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor
prothrombin complex concentrate in patients on vitamin K antagonists
presenting with major bleeding: a randomized, plasma-controlled,
phase IIIb study. Circulation. 2013;128(11):1234–43. doi:10.1161/
CIRCULATIONAHA.113.002283.
98. Ray B, Keyrouz SG. Management of anticoagulant-related intracranial
hemorrhage: an evidence-based review. Crit Care. 2014;18(3):223–3.
doi:10.1186/cc13889.
99. Roquer J, Rodríguez Campello A, Gomis M, Ois A, Puente V, Munteis E.
Previous antiplatelet therapy is an independent predictor of 30-day
mortality after spontaneous supratentorial intracerebral hemorrhage.
J Neurol. 2005;252(4):412–6. doi:10.1007/s00415-005-0659-5.
100. Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen E-R, Hillbom M.
Regular aspirin-use preceding the onset of primary intracerebral
hemorrhage is an independent predictor for death. Stroke. 2006;37(1):129–33.
doi:10.1161/01.STR.0000196991.03618.31.
101. Toyoda K, Okada Y, Minematsu K, et al. Antiplatelet therapy contributes
to acute deterioration of intracerebral hemorrhage. Neurology.
2005;65(7):1000–4. doi:10.1212/01.wnl.0000179178.37713.69.
102. Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE. Prior
antiplatelet use does not affect hemorrhage growth or outcome after ICH.
Neurology. 2009;72(16):1397–402. doi:10.1212/01.wnl.0000342709.31341.88.
103. Moussouttas M, Malhotra R, Fernandez L, et al. Role of antiplatelet
agents in hematoma expansion during the acute period of intracerebral
hemorrhage. Neurocrit Care. 2009;12(1):24–9. doi:10.1007/s12028-009-
9290-0.
104. Caso V, Paciaroni M, Venti M, et al. Effect of on-admission antiplatelet
treatment on patients with cerebral hemorrhage. Cerebrovasc Dis.
2007;24(2-3):215–8. doi:10.1159/000104480.
105. Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J. Emergency reversal of
antiplatelet agents in patients presenting with an intracranial hemorrhage: a
clinical review. WNEU. 2010;74(2-3):279–85. doi:10.1016/j.wneu.2010.05.030.
106. Naidech AM, Liebling SM, Rosenberg NF, et al. Early platelet transfusion
improves platelet activity and may improve outcomes after intracerebral
hemorrhage. Neurocrit Care. 2012;16(1):82–7. doi:10.1007/s12028-011-9619-3.
107. Baharoglu MI, Cordonnier C, Salman RA-S, et al. Platelet transfusion versus
standard care after acute stroke due to spontaneous cerebral haemorrhage
associated with antiplatelet therapy (PATCH): a randomised, open-label,
phase 3 trial. Lancet. 2016. doi:10.1016/S0140-6736(16)30392-0.
108. Frontera JA, Lewin III JJ, Rabinstein AA, et al. Guideline for reversal of
antithrombotics in intracranial hemorrhage. Neurocrit Care. 2015;24(1):6–46.
doi:10.1007/s12028-015-0222-x.
109. Naidech AM, Maas MB, Levasseur-Franklin KE, et al. Desmopressin improves
platelet activity in acute intracerebral hemorrhage. Stroke. 2014;45(8):2451–3.
doi:10.1161/STROKEAHA.114.006061.
110. Kapapa T, Röhrer S, Struve S, et al. Desmopressin acetate in intracranial
haemorrhage. Neurol Res Int. 2014;2014:298767–7. doi:10.1155/2014/298767.
111. Tanaka-Esposito C, Chung MK. Selecting antithrombotic therapy for
patients with atrial fibrillation. Cleve Clin J Med. 2014;82(1):49–63.
doi:10.3949/ccjm.82a.140002.
112. Pollack Jr CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran
reversal. N Engl J Med. 2015;373(6):511–20. doi:10.1056/NEJMoa1502000.
113. Yuan ZH, Jiang JK, Huang WD, Pan J, Zhu JY, Wang JZ. A meta-analysis of
the efficacy and safety of recombinant activated factor VII for patients with
acute intracerebral hemorrhage without hemophilia. J Clin Neurosci.
2010;17(6):685–93. doi:10.1016/j.jocn.2009.11.020.
114. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial
conservative treatment in patients with spontaneous supratentorial
intracerebral haematomas in the International Surgical Trial in Intracerebral
Haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387–97.
115. Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial
conservative treatment in patients with spontaneous supratentorial lobar
intracerebral haematomas (STICH II): a randomised trial. Lancet.
2013;382(9890):397–408. doi:10.1016/S0140-6736(13)60986-1.
116. Kobayashi SS, Sato AA, Kageyama YY, Nakamura HH, Watanabe YY,
Yamaura AA. Treatment of hypertensive cerebellar hemorrhage—surgical or
conservative management? Neurosurgery. 1994;34(2):246–1.
117. Kirollos RW, Tyagi AK, Ross SA, van Hille PT, Marks PV. Management of
spontaneous cerebellar hematomas: a prospective treatment protocol.
Neurosurgery. 2001;49(6):1378–7.
118. Mathew P, Teasdale G, Bannan A, Oluoch-Olunya D. Neurosurgical
management of cerebellar haematoma and infarct. J Neurol Neurosurg
Psychiatry. 1995;59(3):287–92.
119. Raco A, Caroli E, Isidori A, Vangelista T, Salvati M. Management of acute
cerebellar infarction: one institution’s experience. Neurosurgery.
2003;53(5):1061–6. doi:10.1227/01.NEU.0000088766.34559.3E.
120. Webb AJS, Ullman NL, Mann S, Muschelli J, Awad IA, Hanley DF. Resolution
of intraventricular hemorrhage varies by ventricular region and dose of
intraventricular thrombolytic: The Clot Lysis: Evaluating Accelerated
Resolution of IVH (CLEAR IVH) program. Stroke. 2012;43(6):1666–8.
doi:10.1161/STROKEAHA.112.650523.
121. Ziai WC, Tuhrim S, Lane K, et al. A multicenter, randomized, double-blinded,
placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated
Resolution of Intraventricular Hemorrhage (CLEAR III). Int J Stroke.
2013;9(4):536–42. doi:10.1111/ijs.12097.
122. International Stroke Conference (ISC) 2016. Abstracts LB12 and LB13.
Presented 18 Feb 2016. http://professional.heart.org/idc/groups/ahamah-
de Oliveira Manoel et al. Critical Care  (2016) 20:272 Page 28 of 29
public/@wcm/@sop/@scon/documents/downloadable/ucm_481854.pdf.
4 Aug 2016.
123. Li Y, Zhang H, Wang X, et al. Neuroendoscopic surgery versus external
ventricular drainage alone or with intraventricular fibrinolysis for
intraventricular hemorrhage secondary to spontaneous supratentorial
hemorrhage: a systematic review and meta-analysis. Quinn TJ, ed. PLoS
ONE. 2013;8(11):e80599. doi:10.1371/journal.pone.0080599.
124. Teernstra OPM, Evers SMAA, Lodder J, Leffers P, Franke CL, Blaauw G.
Stereotactic treatment of intracerebral hematoma by means of a
plasminogen activator: a multicenter randomized controlled trial (SICHPA).
Stroke. 2003;34(4):968–74. doi:10.1161/01.STR.0000063367.52044.40.
125. Morgan T, Zuccarello M, Narayan R, Keyl P, Lane K, Hanley D. Preliminary
findings of the Minimally-invasive Surgery plus rtPA for Intracerebral Hemorrhage
Evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147–51.
126. Cho D-Y, Chen C-C, Chang C-S, Lee W-Y, Tso M. Endoscopic surgery for
spontaneous basal ganglia hemorrhage: comparing endoscopic surgery,
stereotactic aspiration, and craniotomy in noncomatose patients. Surg
Neurol. 2006;65(6):547–55. doi:10.1016/j.surneu.2005.09.032. discussion555–6.
127. Zhou X, Chen J, Li Q, et al. Minimally invasive surgery for spontaneous
supratentorial intracerebral hemorrhage: a meta-analysis of randomized
controlled trials. Stroke. 2012;43(11):2923–30. doi:10.1161/STROKEAHA.112.667535.
128. Middleton S, McElduff P, Ward J, et al. Implementation of evidence-based
treatment protocols to manage fever, hyperglycaemia, and swallowing
dysfunction in acute stroke (QASC): a cluster randomised controlled trial.
Lancet. 2011;378(9804):1699–706. doi:10.1016/S0140-6736(11)61485-2.
129. Fogelholm R, Murros K, Rissanen A, Avikainen S. Admission blood glucose
and short term survival in primary intracerebral haemorrhage: a
population based study. J Neurol Neurosurg Psychiatry. 2005;76(3):349–53.
doi:10.1136/jnnp.2003.034819.
130. Kimura K, Iguchi Y, Inoue T, et al. Hyperglycemia independently increases
the risk of early death in acute spontaneous intracerebral hemorrhage.
J Neurol Sci. 2007;255(1):90–4. doi:10.1016/j.jns.2007.02.005.
131. Godoy DA, Piñero GR, Svampa S, Papa F, Di Napoli M. Hyperglycemia and
short-term outcome in patients with spontaneous intracerebral hemorrhage.
Neurocrit Care. 2008;9(2):217–29. doi:10.1007/s12028-008-9063-1.
132. Tan X, He J, Li L, et al. Early hyperglycaemia and the early-term death in
patients with spontaneous intracerebral haemorrhage: a meta-analysis.
Intern Med J. 2014;44(3):254–60. doi:10.1111/imj.12352.
133. Rincon F, Lyden P, Mayer SA. Relationship between temperature, hematoma
growth, and functional outcome after intracerebral hemorrhage. Neurocrit
Care. 2013;18(1):45–53. doi:10.1007/s12028-012-9779-9.
134. Schwarz S, Häfner K, Aschoff A, Schwab S. Incidence and prognostic
significance of fever following intracerebral hemorrhage. Neurology.
2000;54(2):354–61.
135. Commichau C, Scarmeas N, Mayer SA. Risk factors for fever in the
neurologic intensive care unit. Neurology. 2003;60(5):837–41.
136. Poli S, Purrucker J, Priglinger M, et al. Rapid Induction of COOLing in
Stroke Patients (iCOOL1): a randomised pilot study comparing cold
infusions with nasopharyngeal cooling. Crit Care. 2014;18(5):582–2.
doi:10.1186/s13054-014-0582-1.
137. Raslan AM, Fields JD, Bhardwaj A. Prophylaxis for venous thrombo-embolism
in neurocritical care: a critical appraisal. Neurocrit Care. 2009;12(2):297–309.
doi:10.1007/s12028-009-9316-7.
138. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M,
Sandercock P, et al. Effectiveness of intermittent pneumatic compression in
reduction of risk of deep vein thrombosis in patients who have had a stroke
(CLOTS 3): a multicentre randomised controlled trial. Lancet. 2013;382:516–24.
doi:10.1016/S0140-6736(13)61050-8.
139. Nyquist P, Bautista C, Jichici D, et al. Prophylaxis of venous thrombosis in
neurocritical care patients: an evidence-based guideline: A Statement for
Healthcare Professionals from the Neurocritical Care Society. Neurocrit Care.
2016;24(1):47–60. doi:10.1007/s12028-015-0221-y.
140. Lacut K, Bressollette L, Le Gal G, et al. Prevention of venous thrombosis in
patients with acute intracerebral hemorrhage. Neurology. 2005;65(6):865–9.
doi:10.1212/01.wnl.0000176073.80532.a2.
141. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia
after stroke: incidence, diagnosis, and pulmonary complications. Stroke.
2005;36(12):2756–63. doi:10.1161/01.STR.0000190056.76543.eb.
142. Hinchey JA, Shephard T, Furie K, et al. Formal dysphagia screening protocols
prevent pneumonia. Stroke. 2005;36(9):1972–6. doi:10.1161/01.STR.
0000177529.86868.8d.
143. Kuramatsu JB, Gerner ST, Lucking H, et al. Anemia is an independent
prognostic factor in intracerebral hemorrhage: an observational cohort
study. Crit Care. 2013;17(4):R148. doi:10.1186/cc12827.
144. Chang TR, Boehme AK, Aysenne A, et al. Nadir hemoglobin is associated
with poor outcome from intracerebral hemorrhage. Springerplus.
2013;2:379–9. doi:10.1186/2193-1801-2-379.
145. Naidech AM, Garg RK, Liebling S, et al. Anticonvulsant use and outcomes
after intracerebral hemorrhage. Stroke. 2009;40(12):3810–5. doi:10.1161/
STROKEAHA.109.559948.
146. Claassen J, Jetté N, Chum F, et al. Electrographic seizures and periodic
discharges after intracerebral hemorrhage. Neurology. 2007;69(13):1356–65.
doi:10.1212/01.wnl.0000281664.02615.6c.
147. Stevens RD, Shoykhet M, Cadena R. Emergency neurological life support:
intracranial hypertension and herniation. Neurocrit Care. 2015;23
Suppl 2:76–82. doi:10.1007/s12028-015-0168-z.
148. Zurasky JA, Aiyagari V, Zazulia AR, Shackelford A, Diringer MN. Early
mortality following spontaneous intracerebral hemorrhage. Neurology.
2005;64(4):725–7. doi:10.1212/01.WNL.0000152045.56837.58.
149. Naidech AM, Bernstein RA, Bassin SL, et al. How patients die after intracerebral
hemorrhage. Neurocrit Care. 2009;11(1):45–9. doi:10.1007/s12028-009-9186-z.
150. Diringer MNM, Edwards DFD, Aiyagari VV, Hollingsworth HH. Factors
associated with withdrawal of mechanical ventilation in a neurology/
neurosurgery intensive care unit. Crit Care Med. 2001;29(9):1792–7.
151. Wayangankar SA, Abu-Fadel MS, Aronow HD, et al. Hemorrhagic and
ischemic outcomes after bivalirudin versus unfractionated heparin during
carotid artery stenting: a propensity score analysis from the NCDR. Circ
Cardiovasc Interv. 2013;6(2):131–8. doi:10.1161/CIRCINTERVENTIONS.112.974857.
152. Koch S, Romano JG, Forteza AM, Otero CM, Rabinstein AA. Rapid blood
pressure reduction in acute intracerebral hemorrhage: feasibility and safety.
Neurocrit Care. 2008;8(3):316–21. doi:10.1007/s12028-008-9085-8.
153. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant
activated factor VII for acute intracerebral hemorrhage. N Engl J Med.
2008;358(20):2127–37. doi:10.1056/NEJMoa0707534.
154. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)
investigators. Antihypertensive treatment of acute cerebral hemorrhage.
Crit Care Med. 2010;38(2):637–48. doi:10.1097/CCM.0b013e3181b9e1a5.
155. Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive blood pressure
reduction in acute intracerebral hemorrhage: a meta-analysis. Neurolog.
2014;83(17):1523–9. doi:10.1212/WNL.0000000000000917.
de Oliveira Manoel et al. Critical Care  (2016) 20:272 Page 29 of 29
